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Pluripotent stem cells have the capability to undergo unlimited self-renewal and differentiation into all somatic cell 
types.  They have acquired specific adjustments in the cell cycle structure that allow them to rapidly proliferate, 
including cell cycle independent expression of cell cycle regulators and lax G1 to S phase transition.  However, due 
to the developmental role of embryonic stem cells (ES) it is essential to maintain genomic integrity and prevent 
acquisition of mutations that would be transmitted to multiple cell lineages.  Here we show that several 
modifications in DNA damage response of ES cells accommodate dynamic cycling and preservation of genetic 
information.   ATM-dependent checkpoint signaling cascade is activated after irradiation of ES cells, and induces 
G2/M, but not G1/S cell cycle arrest.  The absence of a G1/S cell cycle arrest promotes apoptotic response of 
damaged cells before DNA changes can be fixed in the form of mutation during the S phase, while G2/M cell cycle 
arrest allows repair of damaged DNA following replication.  Human ES cells express higher level of DNA repair 
proteins, and rely on homologous recombination to repair double strand breaks.  Radiation does not lead to long-
term loss of pluripotency, since irradiated ES cells show transient decrease in the level of pluripotency factor 
transcripts, while protein levels remains stable.  One week after irradiation, ES cells retain capacity to differentiate 
into three germ layers and form teratomas in immunocompromised mice. 
Similarly to ES cells, induced pluripotent stem (iPS) cells are poised to proliferate and exhibit extreme 
sensitivity to DNA damage,  lack of G1/S cell cycle arrest, and express high level of DNA repair genes, suggesting 
that DNA damage responses are controlled by developmental state of the cell. 
Public health significance of this study originates in great promise that human ES and iPS cells hold in cell 
replacement therapies. Since human ES, and particularly iPS, cells represent potential source of cells for clinical and 
pharmaceutical applications, the DNA damage response pathways that maintain genomic integrity need to be studied 
in greater detail.  
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1.0  INTRODUCTION 
Excerpts of this chapter are submitted for publication as a chapter entitled “Cell cycle adaptations and their roles in 
maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells”. Olga Momčilović1, 2, 
Christopher Navara3, Gerald Schatten2, 4 in “Cell Cycle in Development”.  Springer Verlag.  
1Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 2Pittsburgh Development 
Center, Pittsburgh, Pennsylvania, USA, 3Department of Biology, University of Texas at San Antonio, San Antonio, 
Texas, USA, 4Department of Obstetrics and Gynecology, University of Pittsburgh School of Medicine, Pittsburgh, 
Pennsylvania, USA. 
1.1 PUBLIC HEALTH SIGNIFICANCE 
Since life-expectancy has greatly increased in the past century owing to medical breakthroughs, more people are 
expected to live longer and suffer with age-related degenerative diseases, such as Parkinson’s or Alzheimer disease, 
cancer, and other debilitating conditions.  Treatments to some of these conditions exist, but too often they come 
down to costly disease management.  Therefore, as prevalence of chronic and age-related diseases increases, so do 
the accumulating medical bills.  
Stem cells offer great promise in extending patients quality of life by offering higher impact medical care.  
With derivation of patient-specific induced pluripotent stem (iPS) cells, one can imagine endless possibilities 
regarding patient-customized curative therapies.  Induced pluripotent stem cells and embryonic stem (ES) cells 
could provide us with unlimited source of cells for cell replacement therapies, as well as material for drug 
development and toxicity studies.  Idea that one day it would be possible to replace, for example, β-cells in the 
pancreas of diabetic patient with β-cells differentiated from patient-specific iPS cells, and hence avoid long waiting 
and side-effects of heterologous organ transplant is captivating.  However, before iPS or ES cells are used in clinical 
applications, it is essential to understand the risks associated with such therapies.  ES and iPS cells have the ability 
to form tumors comprised of tissues of all three germ layers in immunocompromised mice, and require that safety 
protocols are put in place to ensure efficient and complete differentiation of ES/iPS cells prior to transplantation into 
patients.  Furthermore, understanding their genomic stability is essential in order to define risks of malignant 
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transformation of cells derived from ES or iPS cells. By studying DNA damage responses in ES and iPS cells we 
can gain insight into mechanisms that safeguard genetic information in these cell types. 
1.2 EARLY DEVELOPMENT 
In sexually reproducing species development of a new organism of begins with fusion of one male and one female 
gamete. This process is called fertilization and results in a single cell new organism termed zygote.  Zygote will 
during the course of the several days, exact timing is species-specific, undergo cleavage – cell divisions 
unaccompanied with cell growth, dividing into smaller daughter cells called blastomeres.  Until at least four-cell 
stage all blastomeres are identical and can be segregated so that each can give rise to an embryo and eventually live 
birth.  Sometimes, segregation of the blastomeres occurs spontaneously during pregnancy and results in 
monozygous twins.  Experimentally, splitting of the blastomeres has been accomplished in several mammalian 
species, including non-human primates.  The property of zygote and 4-8 cell stage blastomeres to give rise to the 
whole organism, embryo proper and supportive extraembryonic tissues, is defined as totipotency.   
At the 16-32 cell stage, human embryo undergoes compaction: tight junctions form between outer cells, 
and gap junctions form between the inner cells. This is the first differentiation event during mammalian 
development and results in loss of totipotency due to delineation of the outer cells to trophectoderm (TE), and inner 
cells to inner cell mass (ICM). Trophectoderm cells transport sodium ions, which is followed by water, resulting in 
the formation of the fluid filled cavity with inner cell mass in one side, and surrounded with trophectoderm.  This 
developmental stage is referred to as blastocyst.  Trophectoderm will give rise to the outer layer of placenta, whereas 
ICM cells will give rise to all cell types of the embryo proper, as well as some extraembryonic tissues. The cells that 
Scheme 1:  Restiction of developmental potential during ontogeny. 
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form ICM of blastocyst have restricted developmental potential relative to zygote and early blastomeres, and cannot 
produce the whole organism. Still, ICM cells are capable of differentiating into three primordial germ layers: 
endoderm, mesoderm, and ectoderm, and can produce 220 cell types of an adult organism, but contribute poorly to 
extraembryonic structures; hence, they are referred to as pluripotent.  The restriction of the developmental potential 
is common theme during development: as developing organism becomes increasingly complex the “potency” of the 
cells that make it is gradually restricted. In adult organism stem cells that maintain tissue homeostasis are 
multipotent – they have the ability to differentiate into a limited number of cell types.  Depiction of different stages 
during ontogeny and accompanying restriction of developmental potential is represented in Scheme 1. 
 The next step of the development involves blastocyst implantation into uterine wall and further 
differentiation of the inner cell mass into outer layer called epiblast, or the primary ectoderm, which will eventually 
give rise to the embryo, and inner layer termed hypoblast, or primitive endoderm that will give rise to 
extraembryonic endoderm (Larsen, 2001; Mitalipov and Wolf, 2009).   
1.3 PLURIPOTENT STEM CELLS 
Stem cells are cells with the unique capability to undergo self-renewal and produce more of the same cell type, as 
well as to differentiate into one or more cell types.  In regard to their differentiation potential, or potency, stem cells 
can be classified as pluripotent and multi/oligopotent.  Pluripotent stem cells can differentiate into all cell types of an 
organism, whereas multipotent stem cells have restricted developmental potential and can differentiate into a limited 
number of cell types.  There are several types of pluripotent stem cells – embryonic carcinoma cells, embryonic 
stem cells, epiblast stem cells, embryonic germ cells, as well as induced pluripotent stem cells. 
In order to understand human embryonic stem cells it is instrumental to put them in context of other 
pluripotent stem cells, as well as historical perspective in which they were derived. 
1.3.1 Embryonic carcinoma cells 
Historically the first pluripotent stem cells were derived from teratocarcinomas – malignant tumors originating from 
the germ cells.  Teratocarcinomas are composed of differentiated cells from all three germ layers, as well as 
undifferentiated pluripotent embryonic carcinoma (EC) cells.  Teratocarcinomas can be serially transplanted 
between mice owing to the presence of pluripotent EC cells.  Stable mouse EC cells were derived in 1970s and were 
shown to be capable of indefinite self-renewal, clonal expansion, and multilineage differentiation (Kahan and 
Ephrussi, 1970; Kleinsmith and Pierce, 1964).  They express proteins that are also expressed in the inner cell mass 
(ICM) of the blastocyst such as Ssea1 (Gachelin et al., 1977; Knowles et al., 1978) and were perceived as in vitro 
counterparts of undifferentiated cells of the ICM (Martin, 1980).  In spite of their capacity to differentiate in vitro, 
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mouse EC cells have limited developmental potential in vivo, most likely due to fact they acquire numerous genetic 
aberrations during teratocarcinoma formation, limiting their use to model early development (Atkin et al., 1974). 
Human EC cells were derived several years later (Hogan et al., 1977), but turned out to be very different 
from mouse EC cells.  Human EC cells express different set of cell surface markers (SSEA3 and SSEA4, rather than 
SSEA1), have high rate of aneuploidy, and limited in vitro differentiation potential (Andrews et al., 1982; Kannagi 
et al., 1983).  Although both mouse and human EC cells have limited value in studying early development, their 
discovery provided the concept for pluripotent stem cells and cancer stem cells, and paved the road for future studies 
on these cell types. 
1.3.2 Mouse embryonic stem cells 
The experiments with intact embryo transfer to extrauterine sites and subsequent teratocarcinoma formation at those 
sites led to understanding that the intact embryo contains pluripotent stem cell population (Solter et al., 1970; 
Stevens, 1970).  In 1981 mouse embryonic stem (ES) cells were derived from the ICM of pre-implantation embryos 
(Evans and Kaufman, 1981; Martin, 1981).  Similarly to pluripotent EC cells, mouse ES cells undergo unlimited 
self-renewal, express proteins found in ICM, differentiate into variety of cell types in vitro, and form 
teratocarcinomas when injected into mice.  Unlike EC cells, mouse ES cells maintain stable karyotype in prolonged 
cell culture and contribute to tissues of all three germ layers and germ cells when injected into recipient mouse 
embryos.  Therefore, mouse ES cells are superior relative to EC cells in studying early development.  In addition, 
ability to form chimeric mice by injection of mouse ES cells into recipient blastocyst provided tool for the 
production of transgenic animals (Bradley et al., 1984; Evans and Kaufman, 1981; Martin, 1981). 
Mouse ES cell derivation and propagation in vitro is supported by the use of mitotically inactivated mouse 
embryonic fibroblasts (MEF) as feeder cells and leukemia inhibitory factor (Lif) in the growth medium (Evans and 
Kaufman, 1981; Smith et al., 1988; Williams et al., 1988).  Lif acts through gp130 and Lif receptor (Lifr) to activate 
Janus-associated tyrosine kinases (Jak)/the latent transducer and activator of transcription factor (Stat3).  In the 
presence of serum, activated Stat3 can maintain mouse ES cell self-renewal by itself (Matsuda et al., 1999).  The 
primary target of Lif/Stat3 pathway is Myc and it can promote Lif-independent self-renewal of mouse ES cell 
(Scheme 2) (Cartwright et al., 2005).  Myc is a cellular oncogene that acts as a transcription factor to induce 
expression of cyclin E and promote G1 to S transition (Hooker and Hurlin, 2006).  Lif signaling pathway can also 
activate Erk mitogen activated protein kinase (MAPK) (Takahashi-Tezuka et al., 1998), but the effect of Erk 
activation appears to be negative for self-renewal of mouse ES cells (Scheme 2) (Burdon et al., 1999).  Therefore, 
the balance between Lif promoting and inhibitory effects on mouse ES cells’ self-renewal must be finely adjusted to 
achieve proliferative effect of Lif.   
In serum-free conditions Lif alone is not sufficient to maintain self-renewal of mouse ES cells, and 
additional growth factors, such as bone morphogenic proteins (Bmp) are required (Scheme 2).  Bmp signal 
activation of inhibitor of differentiation (Id) via Smad1/5/8 pathway (Ying et al., 2003).  Overexpression of Id 
proteins can bypass the need for Bmp signaling, further supporting their role in mouse ES cell maintenance.  In 
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addition, Bmp have Smad-independent inhibitory effect on differentiation of mouse ES cells by suppressing p38 
Mapk (Qi et al., 2004).  
Phosphatidylinositol 3 kinase (Pi3k) signaling pathway is essential for mouse ES cells’ self-renewal as well 
(Scheme 2).  Inhibition of Pi3k signaling induces differentiation even in the presence of Lif (Welham et al., 2007), 
and constitutively active Pi3k downstream target Akt maintains undifferentiated state of mouse and primate ES cells 
(Watanabe et al., 2006).  The positive effect of Pi3k on mouse ES cell proliferation is at least in part due to 
inhibition of Myc negative regulator, glycogen synthase kinase 3 (Gsk3) (Cartwright et al., 2005; Sato et al., 2004).  
Pi3k itself is thought to be regulated by Lif directly or indirectly, as well as by other medium components such as 
insulin/insulin-like growth factor (Igf).  
More recently mouse epiblast pluripotent stem cells (EpiSC) have been isolated from the early post-
implantation embryos.  Although epiblast stem cells share common features with mouse ES cells, such as self-
renewal and multilineage differentiation, they exhibit prominent differences.  Interestingly, characteristics that 
distinguish EpiSC from mouse ES cells, including cell culture medium requirements, gene expression pattern and 
colony morphology, are shared with human ES and iPS cells (Brons et al., 2007; Tesar et al., 2007).  
 
Scheme 2:  Extrinsic signaling pathways required for maintenance of mouse embryonic stem cell self-
renewal. 
1.3.3 Embryonic germ cells 
In 1992 mouse embryonic germ (EG) cells were isolated from primordial germ cells (PGC) in vitro (Matsui et al., 
1992; Resnick et al., 1992).  These cells are morphologically indistinguishable from mouse ES cells and share 
numerous similarities: express similar pluripotency markers (Oct4 and Ssea1), and contribute to multitude of tissues 
in chimeric mice, including germ cells (Labosky et al., 1994; Stewart et al., 1994).  However, EG cells retain some 
of the characteristics of the PGC from which they were derived that distinguish them from mouse ES cells.  For 
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example, unlike mouse ES cells, mouse EG cells have global genome demethylation, erased genome imprints and 
reactivate X chromosome (Labosky et al., 1994; Tada et al., 1997).   
1.3.4 Human embryonic stem cells 
Even though mouse ES cells became available in the early 1980s, there was substantial delay in derivation of human 
ES cells.  Human ICM were successfully isolated in the early 1990s, but would soon differentiate in vitro under the 
same culture conditions that supported mouse ES cell derivation (Bongso et al., 1994).  Derivation of non-human 
primate ES cells (Thomson et al., 1995; Thomson et al., 1996) helped define culture conditions for successful 
derivation of the first human ES cell lines from the surplus in vitro fertilized (IVF) blastocyst stage embryos in 1998 
by Thomson and colleagues (Thomson et al., 1998). 
Similar to mouse ES cells, human ES cells undergo self-renewal in vitro and maintain stable karyotype for 
prolong periods of cell culture.  Importantly, human ES cells can differentiate into numerous cell types of all three 
germ layers in vitro, and following injection into immunocompromised mice form teratocarcinomas.  However, 
human ES cells exhibit some prominent differences in comparison to mouse ES cells: human ES cells express cell 
surface markers SSEA3, SSEA4, TRA-1-60, and TRA-1-81, which are expressed in mouse EpiSC, but are not 
present in mouse ES cells.  Furthermore, the maintenance of self-renewal of human ES cells appears to be regulated 
by different extrinsic factors.  For example, the first attempts to derive human ES cells from human blastocysts 
using the same conditions as for mouse ES cells, such as presence of LIF and serum in culture medium, failed 
because isolated human ES cells differentiated (Bongso et al., 1994).  The similarities and differences between 
mouse and human ES cells are summarized in Table 1. 
Scheme 3:  Extrinsic signaling pathways required for maintenance of self-renewal in human 
embryonic stem cells. 
Undifferentiated state of human ES cells is sustained by the basic fibroblast growth factor (FGF2) (Amit et 
al., 2000; Xu et al., 2001), TGFB/activin A and PI3K signaling activators, such as IGF, similar to mouse epiblast 
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stem cells (Brons et al., 2007; Tesar et al., 2007), Scheme 3.  In contrast to mouse ES cells, LIF and BMP cause 
differentiation of human ES cells (Xu et al., 2002).  The key extrinsic signaling factors needed for human ES cell 
self-renewal are represented in Scheme 3. 
Table 1:  Comparison of characteristics of mouse and human embryonic stem cells. 
Properties Mouse ES cells Human ES cells 
Prolonged propagation in 
undifferentiated state 
  
Maintain normal karyotype   
Pluripotent 
Directed differentiation in                    
vitro 















High nucleus to cytoplasm 
ratio 
  
Telomerase activity   
Alkaline phosphatase activity   
OCT4   
NANOG   
Ssea1   
SSEA3   
SSEA4   
TRA-1-60   
TRA-1-81   
Lif and Bmp dependent for 
self-renewal 
  
FGF2 and TGFB dependent 
for self-renewal 
  
X-chromosome activation  Line dependent 
Imprinting Commonly lost  
Basic fibroblast growth factor is thought to act through direct activation of transcriptional factors involved 
in self-renewal, suppression of BMP signaling, and by stimulating autocrine effects.  When grown in the presence of 
feeder cells, lower concentration of FGF2 (4 ng/ml) is sufficient to maintain human ES cells.  However, in feeder-
free conditions, either higher concentrations of FGF2 have to be used (100 ng/ml), or BMP signaling inhibitor, such 
as noggin, has to be supplemented in combination with medium FGF2 concentration (40 ng/ml) (Wang et al., 2005; 
Xu et al., 2005a; Xu et al., 2005b).  Suppression of BMP alone is not sufficient to maintain human ES cells’ self-
renewal, suggesting that FGF2 has additional functions (Xu et al., 2005b).  It has been demonstrated that FGF2 
promotes secretion of TGFB ligands and inhibits expression of BMP4 in both feeder and human ES cells (Greber et 
al., 2007).  Activin A, TGFB ligand, stimulates FGF2 secretion creating a positive feedback loop between 
TGFB/activin A and FGF2 signaling pathways that is responsible for maintenance of human ES cells’ self-renewal.  
It also explains growth factor requirements: at lower FGF2 concentrations it is necessary to supplement medium 
with TGFB signaling factors, while at higher concentrations of one factor the dependence of human ES cell culture 
on the other factor is greatly reduced (Ludwig et al., 2006; Vallier et al., 2005; Xiao et al., 2006). 
In addition to stimulating FGF2 secretion, TGFB/activin A signals through SMAD2/3 phosphorylation and 
activation.  SMAD2/3 can suppress SMAD1/5 activity, which is involved in BMP signaling, suggesting that 
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TGFB/activin A negatively regulate BMP signaling in human ES cells (Beattie et al., 2005; James et al., 2005).  
FGF2 can inhibit nuclear translocation of phospho-SMAD1 thereby assisting TGFB/activin A in suppressing BMP 
activity (Xu et al., 2005b).  More recently, it has been reported that NANOG and POU5F1 are direct transcriptional 
targets of TGFB/activin A pathway (Babaie et al., 2007), providing a direct link between extrinsic and intrinsic 
regulators of human ES cells’ state.  
PI3K signaling pathway may act in human ES cells through suppression of GSK3. Sato and colleagues 
showed that GSK3 suppression is essential for human ES cell self-renewal short-term (Sato et al., 2004).  
Furthermore, WNT signaling, which results in inhibition of GSK3B, a target common to PI3K pathway, leads to 
increased SMAD2/3 phosphorylation and promoted pluripotency of human ES cells (James et al., 2005). 
1.4 CORE TRANSCRIPTIONAL FACTORS THAT REGULATE PLURIPOTENCY 
Three transcription factors have been demonstrated to be central to the maintenance of ES cells’ pluripotency: 
NANOG, OCT4 and SOX2. 
NANOG is a homeodomain protein with specific expression in pre-implantation embryos and ES cells.  
Mitsui et al. (Mitsui et al., 2003) showed that NANOG actively maintains self-renewal of mouse ES cells and that 
deletion of the NANOG gene results in loss of pluripotency in both ICM and ES cells.  NANOG disruption in mice 
resulted in embryos composed of disorganized extraembryonic tissues with no discernable epiblast or 
extraembryonic ectoderm, and ICMs from NANOG null blastocysts failed to proliferate in vitro.  NANOG 
downregulation in mouse (Chambers et al., 2003; Mitsui et al., 2003) and human (Hyslop et al., 2005) ES cells 
resulted in expression of a number of endoderm transcription markers, indicating that NANOG disruption specified 
ES cell fate into extraembryonic endoderm lineages.  Furthermore, Chambers et al. (Chambers et al., 2003) showed 
that forced expression of NANOG confers self-renewal on mouse ES cells and suppresses ES differentiation in 
response to retinoic acid.   
POU5F1 (OCT4) is a member of PIT/OCT/UTF (POU) family of transcription factors that is expressed in 
the ICM, epiblast, primordial germ cells, and unfertilized oocytes (Hansis et al., 2000; Palmieri et al., 1994).  It is 
rapidly down-regulated during retinoic acid-induced differentiation of mouse ES cells (Okamoto et al., 1990).  In 
vivo, OCT4 is absent from trophectoderm, indicating that it acts to prevent differentiation into trophectoderm 
(Nichols et al., 1998; Niwa et al., 2000; Palmieri et al., 1994).  Pou5f1 knock-out embryos fail to form ICM.  Unlike 
NANOG, whose upregulation prevents differentiation, increased levels of Oct4 lead to differentiation into primitive 
endoderm and mesoderm in mouse ES cells (Niwa et al., 2000).  The pattern of ES cell differentiation following 
manipulation of POU5F1 levels is distinct in human ES cells: downregulation of POU5F1 resulted in increase of 
endoderm and mesoderm marker expression, whereas upregulation induced markers for endoderm derivatives 
(Rodriguez et al., 2007).  Thus, POU5F1 must be kept within a critical range of expression in order to maintain 
pluripotent phenotype in both mouse and human ES cells (Niwa et al., 2000; Rodriguez et al., 2007).   
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OCT4 binds to SRY-related HMG box family member SOX2 to regulate target genes (Yuan et al., 1995).  
Sox2 null embryos die post-implantation, and Sox2 knock-down mouse ES cells differentiate into multiple lineages 
(Ivanova et al., 2006).  However, SOX2 overexpression leads to differentiation, suggesting that SOX2 levels must be 
tightly regulated, similar to OCT4, in order to maintain pluripotency (Fong et al., 2008). 
OCT4, SOX2 and NANOG are master regulators of transcriptional network that controls early 
development and specifies undifferentiated state in both mouse and human ES cells (Chambers et al., 2003; Hart et 
al., 2004; Mitsui et al., 2003; Nichols et al., 1998).  They bind together to the promoters and activate the number of 
genes that encode transcriptional factors, chromatin remodeling enzymes and micro RNA that maintain self-renewal 
and pluripotency in ES cells.  OCT4, SOX2 and NANOG exert both activating and repressing effects on large 
groups of genes. The positively regulated genes include: (1) genes for OCT4, SOX2 and NANOG themselves, 
creating a positive autoregulatory circuit, (2) genes for other transcription factors and components of signaling 
pathways (such as TGFBand WNT) that promote undifferentiated state and self-renewal in human ES cells, and (3) 
genes for chromatin remodeling that regulate epigenetic profile of ES cells.  In contrast, the group of repressed 
genes is enriched in transcription factors that are involved in differentiation into ectoderm, mesoderm and endoderm 
lineages (Boyer et al., 2005).  Therefore, these three master transcription factors maintain pluripotency by activating 
genes essential for self-renewal, while repressing genes involved in differentiation.   
In addition to the above described network of transcriptional factors, pattern of epigenetic marks influences 
the gene expression, and is unique to the cell type and developmental stage.  Epigenetic control of gene expression is 
based on inheritable DNA and histone modifications that alter local chromatin structure and DNA accessibility.  ES 
cells are characterized by generally open chromatin structure that is permissive for gene expression.  As ES cells 
differentiate chromatin becomes gradually more condensed and restrictive.  Genes for chromatin remodeling 
enzymes, such as those involved in DNA methylation and histone modifications are also regulated by OCT4, SOX2 
and NANOG (Boyer et al., 2005).  Through combination of DNA methylation, activating (histone 3 lysine 4 
trimethylation, histone 3 and histone 4 acetylation) and repressing (histone 3 lysine 9 and lysine 27 trimethylation) 
histone marks, as well as regulation of nucleosome positioning and conformation, remodeling of local chromatin 
structure adds additional layer to transcriptional control in ES cells and affects balance between self-renewal and 
differentiation (Fouse et al., 2008; Keenen and de la Serna, 2009).  Therefore, in additional to their direct 
transcriptional control, OCT4, SOX2 and NANOG affect the gene expression profile in ES cells by regulating 
expression of chromatin remodeling enzymes that define pattern of epigenetic marks.  
1.5 NUCLEAR REPROGRAMMING AND INDUCED PLURIPOTENT STEM CELLS 
Xenopus laevis somatic nuclear transfer into enucleated eggs and production of fertile animals demonstrated that 
differentiation process, until then regarded as unidirectional process, can be reversed (Gurdon and Uehlinger, 1966).  
These experiments established for the first time that genomes of somatic cells contain information needed for 
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development of entire organism, and that oocytes contain factors that can mediate the reprogramming of 
differentiated cells into pluripotent cells.   
The major advancement in mammalian somatic cell reprogramming was achieved by generation of the first 
cloned mammal, sheep Dolly (Campbell et al., 1996), by somatic cell nuclear transfer.  This process utilizes 
enucleated oocyte to reprogram transferred somatic cell into totipotent state.  All differentiation marks are stripped 
and such “reprogrammed” nucleus can direct development to live birth.  Dolly, as well as clones of other 
mammalian species, showed that it is possible to reverse differentiation of completely matured adult somatic cells in 
mammals.  This crucial finding was further extended to primates with derivation of cloned ES cells from rhesus 
macaque blastocysts developed from enucleated oocyte injected with adult skin fibroblasts (Byrne et al., 2007). 
The process of nuclear reprogramming using eggs is very inefficient and depends on the availability of 
oocytes, rendering it highly controversial in humans.  In addition, the efficiency of nuclear reprogramming by eggs 
greatly diminishes as donor cell becomes increasingly differentiated.  The previous work with transcription factor 
induced reprogramming demonstrated that forced expression or deletion of individual lineage specific 
transcriptional factors could induce lineage conversion in differentiated somatic cells.  For example, expression of 
myogenic transcription factor MYOD could convert fibroblasts into muscle cells (Davis et al., 1987), whereas 
expression of CEBPA in mature B cells resulted in their reprogramming into macrophages (Xie et al., 2004).  
Furthermore, similar principle was found to be true in embryonic cells: overexpression of trophectoderm specifier 
Cdx2 in mouse ES cells resulted in their differentiation into trophectoderm (Niwa et al., 2005), whereas expression 
of endoderm specific transcriptional factors Gata4 and Gata6 in ES cells induced formation of primitive endoderm 
(Fujikura et al., 2002).  These experiments provided the rational for the next step in cell reprogramming: to 
reprogram somatic cells into pluripotent cells by overexpression of transcription factors. 
Somatic cells were successfully reprogrammed into pluripotent state first in mouse (Takahashi and 
Yamanaka, 2006), and then in human (Takahashi et al., 2007; Yu et al., 2007) using defined set of transcriptional 
factors.  The reprogrammed somatic cells are similar to ES cells in morphology, proliferation, expression of ES cell 
markers, as well as teratoma formation, and are referred to as induced pluripotent stem (iPS) cells.  Initial studies 
required 24 retrovirally carried transgenes that are preferentially expressed in ES cells, but the factors were then 
reduced to four key transcription factors: Pou5f1, Sox2, Klf4 and Myc (Takahashi and Yamanaka, 2006).  At the 
same time when human iPS cells were produced with these four factors (Takahashi et al., 2007), another group 
derived human iPS cells with another set of four transcription factors: NANOG, POU5F1, LIN28 and SOX2 (Yu et 
al., 2007).  The process of somatic cell reprogramming with defined factors is gradual process and is depicted in 
Scheme 4.  Use of morphological criterion to identify iPS cells frequently leads to isolation of partially 
reprogrammed cells.  These cells exhibit incomplete DNA demethylation and activation of endogenous pluripotency 
genes, express viral transgenes and lineage genes that are not expressed in the starting population of cells.  Inhibition 
of differentiation pathways greatly improves reprogramming, and facilitates full reprogramming of the partially 
reprogrammed cells (Mikkelsen et al., 2008).  Completely reprogrammed iPS cells have silenced transgenes, express 
telomerase, reactivate silenced X chromosome, and have gene expression and epigenetic marks similar to ES cells 
(Mikkelsen et al., 2008; Okita et al., 2007).  Functionally, mouse iPS cells form chimeric mice and contribute to the 
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germ line proving that they are indeed pluripotent (Hanna et al., 2008; Kim et al., 2008).  Human iPS cells, however, 
cannot be tested in this manner, but have been shown to differentiate in multitude of cell types in vitro, and to form 
teratocarcinomas when injected into immunocompromised mice.  
 
Scheme 4:  Steps in somatic cell reprogramming using defined transgenes. 
Three of transgenes used in reprogramming cocktail, OCT4, NANOG and SOX2 comprise a vital 
transcriptional network that maintains ES cells’ self-renewal and were already discussed.  KLF4 shares many DNA 
targets with NANOG and its downregulation leads to differentiation.  MYC is central for self-renewal in mouse ES 
cells, as has been already described, but its overexpression in human ES can  promote differentiation (Sumi et al., 
2007).  It is dispensable for somatic cell reprogramming and can be left out from the reprogramming cocktail in 
mouse and human (Nakagawa et al., 2008).  LIN28 blocks processing of micro RNA involved in differentiation, 
thereby inhibiting micro RNA mediated differentiation (Viswanathan et al., 2008).  
Since the first experiments, iPS have been generated from various cell types both in mouse (Aoi et al., 
2008; Hanna et al., 2008; Kim et al., 2008) and human (Aasen et al., 2008; Loh et al., 2009), and have been 
generated from patients with various genetic diseases (Park et al., 2008).  Importantly, human iPS cells have been 
recently derived without viral integration and free from transgene sequences (Yu et al., 2009), making them much 
safer for prospective clinical applications. 
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1.6 POTENTIALS AND PROBLEMS WITH USE OF PLURIPOTENT STEM CELLS 
1.6.1 Human embryonic stem cells 
Differentiation potential of ES cells makes them excellent candidates for source for cell replacement therapies.  
Human ES cell derived differentiated cells have been used to treat animals with spinal cord injury (Keirstead et al., 
2005), retinal disease (Lamba et al., 2009) and Parkinson’s disease (Yang et al., 2008).  The US Food and Drug 
Administration (FDA) allowed the first clinical trials for use of human ES cells for therapy of spinal cord injury in 
January 2009.  In addition to potentially treating numerous diseases, ES cells can be used to model human diseases.  
This approach is particularly valuable when affected tissues cannot be obtained from human subjects – such as in 
case of Alzheimer’s patients.  ES cells might prove very useful for drug discovery – coupled with modeling of 
human diseases in vitro, one can imagine that such tissues can be used to test novel molecules as potential 
therapeutics.  Finally, human ES cells are currently indispensable as the only model for understanding of the early 
human development. 
In spite of their tremendous potential, human ES cells pose serious problems.  Although embryos used for 
human ES cell derivation are most often surplus IVF embryos that would not be used for reproduction, for many 
people use of human ES cells for clinical purposes presents itself with serious ethical concern:  in the very nature of 
derivation of ES cells lays destruction of the human embryos.  The question comes to whether one is going to use 
these cells for own benefit, at the expense of an embryo?  There is a limited number of available human ES cell 
lines, and they are genetically different than prospective patients; hence any potential replacement therapy carries an 
inherent risk of tissue rejection. In addition, the existing human ES cells have been derived using the animal 
products, raising the possibility of xeno-contamination in prospective therapies.  Undifferentiated ES cells have 
strong potential to form malignant tumors in vivo recipients. Therefore, stringent safety protocols must be devised to 
prevent malignant transformation of incompletely differentiated cells. 
1.6.2 Human induced pluripotent stem cells 
Induced pluripotent cells are promising source for cell replacement therapies as they have wide developmental 
potential, similar to ES cells.  Furthermore, because iPS cells are derived from reprogrammed somatic cells, the 
process of derivation does not involve embryo destruction, and accompanying ethical issues.  Induced pluripotent 
stem cells can be derived from each patient individually, therefore eliminating the risk of rejection of genetically 
(and hence, immunologically) distinct cells/tissue.  In addition, iPS technology enables production of ES cell-like 
cells from patients with complex genetic diseases which could be then used for understanding of disease pathology 
and drug screening.  Indeed, patient-specific iPS cells have been derived from patients with diabetes (Park et al., 
2008), Parkinson’s disease (Soldner et al., 2009), amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008), and 
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spinal muscular dystrophy (SMD) (Ebert et al., 2009).  Cells differentiated from iPS cells were shown to alleviate 
symptoms of Parkinson’s disease and sickle cell anemia in mouse (Hanna et al., 2007; Wernig et al., 2008).  
Similar to ES cells, iPS cells carry certain concerns that include risk of tumor formation following 
transplantation of incompletely differentiated stem cells, particularly because current protocols rely on use of 
oncogenic sequences for reprogramming.  Although transgenes are silenced during the course of somatic cell 
reprogramming, there is still a risk of transgene reactivation, especially in case of powerful, oncogenes such as 
MYC.  Indeed, Okita et al. (Okita et al., 2007) study demonstrated that 50% of chimeric mice generated from iPS 
developed tumors.  Furthermore, leaky transgene expression may also render iPS resistant to differentiation and 
maturation, further increasing the risk of tumorigenesis. Some studies show that iPS cells are not identical to ES 
cells, at least in terms of epigenetic modifications.  Finally, it is not known whether obtained iPS are fully 
reprogrammed, or to which extent they are, suggesting there is a significant heterogeneity even within the same line.  
Taken together these concerns greatly affect their usefulness, as well as safety.  
1.7 CELL CYCLE REGULATION  
1.7.1 Somatic cells 
The basic function of the cell cycle is to ensure accurate duplication of genetic information and equal segregation of 
copied DNA between two daughter cells.  DNA replication occurs during the S phase of the cell cycle, after which 
copied DNA molecules are separated during the mitosis (M phase) into two daughter cells.  S and M phases are 
separated by the growth phases, G1 and G2, during which cell prepares itself for the DNA duplication and cell 
division.  Progression through the cell cycle is tightly regulated by both extrinsic and intrinsic factors.  Deregulation 
of the cell cycle control may have serious consequences and is part of the malignant transformation. 
G1 phase of the cell cycle is the time between exit from the mitosis and the next round of DNA replication.  
During this period cells are particularly sensitive to the intracellular and extracellular signals and decide their fate – 
whether they will go into the S phase, pause in G1, senesce or become quiescent.   In case that the environment is 
favorable and signals for division are present, cell will traverse through the restriction point – a point in G1 phase 
after which cell is committed to replicate DNA, even if the extracellular signals that stimulate cell division are 
removed afterwards.  Such extracellular signals that stimulate cell division are referred to as mitogens.  They act to 
remove brake systems that inhibit the progression to the S phase.  
At the molecular level, the passage through the restriction point and G1 to S transition is regulated by 
concerted series of protein phosphorylations and dephosphorylations, as well as timed expression of cell cycle 
regulators.  It is driven by cyclin dependent kinases (CDK), which are kept inactive in the absence of proliferation 
signals.  Their activity is dependent upon presence of the binding partners, cyclins, whose levels oscillate throughout 
the cell cycle and are tightly regulated (Scheme 5).  However, cyclin binding is not sufficient and cdk activation 
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involves removal of inhibitory phosphate groups by CDC25 phosphatases, as well as phosphorylation at the 
activating sites by cyclin activating kinase (CAK).  Finally, CDK activity can be blocked by binding of CDK 
inhibitory proteins belonging to INK4 family (CDKN2B, CDKN2A, CDKN2C, CDKN2D) and CIP/KIP family 
(p21 and CDKN1B) that directly inhibit CDK activity.  
 
Scheme 5:  Oscillation of cyclin protein level and cyclin/cdk activity throughout the cell cycle 
(Forsburg, 2000). 
Mitogens act through cell surface receptors to activate mitogen activated protein (MAP) kinase cascade 
resulting in increased levels of MYC transcription factor (Scheme 6).  MYC promotes expression of D cyclins 
which bind to and activate CDK4 and CDK6, triggering the phosphorylation of retinoblastoma (RB) family 
members (p105, p107 and p130).  RB proteins are negative regulators of cell proliferation because they bind to and 
sequester E2F transcriptional factors that are required for the entry into the S phase.  RB phosphorylation by cyclin 
D/CDK4 and cyclin D/CDK6 results in its partial inhibition and E2F release, followed by expression of E2F target 
genes, such as cyclin E, cyclin A, H2A, PCNA, as well as E2F, creating an amplifying loop.  Cyclin E binds to 
CDK2 which further phosphorylates RB, resulting in its complete inactivation, and passage through the R point.  
Besides the kinase dependent function in inactivating RB, cyclin D/CDK4 and cyclin D/CDK6 assist in cyclin 
E/CDK2 activation by titrating away their inhibitors.  As cyclin E/CDK2 activity peaks in late G1, mitogen-
dependent cyclin D/CDK4 and cyclin D/CDK6 activity is no longer necessary.   
G2 phase of the cell cycle is the period between the exit from the S phase and entry into mitosis. Transition 
from the G2 to mitosis is dependent on the activity of CDK1, and is controlled by the availability of its binding 
partner, cyclin B, as well as posttranslational modifications of CDK1.  CDK1 and cyclin B together form the 
maturation promoting factor (MPF) (Yamashita et al., 1992), which phosphorylates numerous substrates.  The MPF 
targets include lamins whose phosphorylation leads to nuclear envelope breakdown (Peter et al., 1991), condensins 
that control chromosome condensation (Kimura et al., 1998), as well as microtubule associated proteins and motor 
proteins that are involved in centrosome separation and mitotic spindle formation (Blangy et al., 1995). 
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Scheme 6:  Regulation of transition from G1 to S phase of the cell cycle. 
Level of cyclin B is set by balancing its gene transcription with protein degradation and peaks in late G2 
and early mitosis (Scheme 5).  CCNB gene expression is activated by transcription factors that are under control of S 
phase specific cyclin A/CDK2 complex in order to ensure its timely expression (Chae et al., 2004; Dynlacht et al., 
1994; Ziebold et al., 1997).  Cyclin B is rapidly degraded by anaphase promoting complex (APC), an E3 ubiquitin 
ligase that targets cyclin B for proteosomal degradation in the early mitosis (Acquaviva and Pines, 2006).  CDK1 is 
activated once the cyclin B protein level reaches certain threshold, but full activation is achieved by posttranslational 
modifications of CDK1.  Fine tuning of cdk1 function is regulated by opposing effects of CDC25 phosphatase and 
WEE1/MYT1 kinases.  WEE1 and MYT1 place inhibitory phosphate groups on tyrosine 14 and tyrosine 15 in 
CDK1 (Booher et al., 1997; Liu et al., 1997).  These negative marks are removed by CDC25 phosphatases.  In 
addition, CDK1 has to be phosphorylated at threonine 161 by CAK for its full activation (Scheme 7) (Atherton-
Fessler et al., 1993; Gould and Nurse, 1989; Tassan et al., 1994).   
Once activated, cyclin B/CDK1 can phosphorylate and thereby inactivate WEE1 and MYT1, further 
promoting its own activation (Watanabe et al., 2005; Watanabe et al., 2004).  It can also help activate CDC25 
through phosphorylation, further enhancing the amplification of MPF signaling (Hoffmann et al., 1993).     
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There is a parallel regulatory pathway of onset of mitosis that relies on activation of Polo like kinase (PLK) 
1.  PLK1 is a positive regulator of mitotic entry and is involved in centrosomes maturation, formation of bipolar 
spindle, chromosome segregation, as well as cyclin B/CDK1 activation (Alexandru et al., 2001; Yarm, 2002).  PLK1 
is activated by aurora A/BORA phosphorylation at threonine 210 (Seki et al., 2008).  PLK1 phosphorylates 
CDC25C at seine 198 resulting in CDC25C activation (Roshak et al., 2000; Toyoshima-Morimoto et al., 2002), 
while phosphorylation of negative regulators of mitotic entry Wee1 and Myt1 leads to their inactivation (Inoue and 
Sagata, 2005; Nakajima et al., 2003) (Scheme 7).  PLK1 can also directly phosphorylate cyclin B (Toyoshima-
Morimoto et al., 2001).  Activated cyclin B/cdk1 phosphorylate BORA, which enhances aurora A/BORA binding to 
and activation of PLK1 (Chan et al., 2008; Hutterer et al., 2006), ultimately leading to further stimulation of cyclin 
B/CDK1 activity and mitotic entry. 
Scheme 7:  Regulation of transition from G2 to mitosis. 
1.7.2 Mouse embryonic stem cells  
ES cell self-renewal is maintained at least in part by promotion of cellular proliferation.  It is not surprising then that 
ES cells have specific adjustments to the cell cycle regulation that allow them to rapidly proliferate.   
Mouse ES cells are characterized by very short cell cycle (11 – 16 hours), predominantly because of the 
short G1 phase that accounts for about 15% of the cell cycle time (2 hours) (Savatier et al., 1994).  The cyclin 
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E/Cdk2 activity in mouse ES cells is high and cell cycle independent (unlike in somatic cells where it peaks at the 
G1 to S transition, Scheme 5), and cyclin A/Cdk2 is constitutively active.  Retinoblastoma tumor suppressor (Rb) is 
held inactive by hyperphosphorylation throughout the cell cycle, leading to constitutive E2f activation, and non-
phasic transcription of E2f target genes (Stead et al., 2002).  The D-type cyclin expression is very low, whereas 
Cdk4 kinase activity is almost undetectable, providing evidence that mitogen-induced cyclin D/Cdk4 or cyclin 
D/Cdk6 activity do not have a role in regulating Rb/E2f and subsequently cyclin E/Cdk2 activity (Savatier et al., 
1994; Savatier et al., 1996).  The only cell cycle regulators expressed in cell cycle dependent manner are cyclin B 
and Cdk1, which are expressed at the G2 to mitosis transition (Stead et al., 2002).  These findings are consistent with 
the observation that restriction point is bypassed in mouse ES cells, resulting in facilitated G1 to S transition and 
proliferation.  Following differentiation, restriction point is acquired; Rb/E2f and cyclin E come under mitogen-
dependent activity of cyclin D/Cdk4 or cyclin D/Cdk6 complexes and become cell cycle regulated (Savatier et al., 
1996; White et al., 2005).   
Lif/Stat3/Myc pathway has major role in maintaining mouse ES cell self-renewal by promoting 
proliferation: Myc is a major target of Lif/Stat3 pathway and is powerful inducer of cyclin E expression, stimulating 
G1 to S transition.  Therefore, there is a link between regulation of self-renewal and cell cycle control in mouse ES 
cells.  The benefit of having shorter G1 phase in not only in achieving rapid proliferation, but also in avoiding 
differentiation signals that are active during early G1 in other cell types.   
1.7.3 Non-human primate embryonic stem cells 
Non-human primate ES cells have slightly longer cell cycle duration than mouse ES cells: 12 – 21 hours, with 
median cell cycle duration of 15 hours.  Over 50 % of cells are found in the S phase, and the expression of cyclin E 
and cyclin A is high.  Following differentiation, the fraction of cells in the S phase, as well as the level of cyclin E 
and cyclin A, is decreased.  Similar to the observations in the mouse ES cells, cyclin E expression and RB 
hyperphosphorylation are independent of the cell cycle stage, but unlike mouse ES cells, cyclin A exhibits transient 
expression in cell cycle.  In addition, non-human primate ES cells do not require serum in the medium, and MAPK 
activity does not affect the growth rate (Fluckiger et al., 2006).   
1.7.4 Human embryonic stem cells 
Human ES cells’ cell cycle is abbreviated similar to mouse and non-human primate ES cells, with median cell cycle 
duration of 15.8 hours.  Shortening of the G1 phase is responsible for abbreviated cell cycle in human ES cells.  G1 
phase accounts for about 19% of the cell cycle, corresponding to 2.5-3 hours.  Vast majority of cells are in the S 
phase that lasts about 8 hours.  In healthy human ES cell cultures all cells are positive for proliferation marker KI-
67, demonstrating the absence of quiescent cells (Becker et al., 2006).  Unlike in mouse ES cells, in human ES cells 
most of the cell cycle regulators including cyclins D2, E and A exhibit phase-specific expression (Neganova et al., 
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2009); the comparison of expression of key cell cycle controllers between mouse and human ES cells is summarized 
in Table 2.  Becker and colleagues demonstrated that the expression of CDK4 is higher than that of CDK6 in human 
ES cells, and that cyclin D2 expression is elevated in human ES cells in comparison to somatic cells.  Furthermore, 
the expression of CDK inhibitors CDKN1A, CDKN1B and CDKN1C is barely detectable.  Thus, in comparison to 
mouse ES cells, human ES cells exhibit more prominent control of the cell cycle progression, particularly through 
G1 phase.  Nevertheless, human ES cells still exhibit shortened G1 phase and rapid proliferation, and results suggest 
that this is result of elevated cyclin D2/CDK4 activity (Becker et al., 2006).  
As already mentioned, self-renewal is supported by rapid proliferation.  Since self-renewal is under control 
of NANOG, OCT4, and SOX2 transcription factors, it is reasonable to speculate that there is a link between 
transcriptional network that controls self-renewal and regulation of proliferation.  Indeed, NANOG has been found 
to accelerate G1 to S transition, as well as S phase progression in human ES cells through direct transcriptional 
activation of CDK6 and CDC25A gene expression.  Overexpression of NANOG suppresses the spontaneous 
differentiation and promotes human ES cells’ expansion, without affecting the apoptosis (Zhang et al., 2009). 
Table 2:  Comparison of expression and activity of cell cycle controllers in mouse and human embryonic stem 
cells. 
 Mouse ES cells Human ES cells 
Cyclin D Very low High in G1 
CDK4 Almost undetectable High activity in G1 
CDK6 High G1  
Cyclin E/CDK2 Constitutively active G1 – S 
CDC25A  G1 
Cyclin A/CDK2 Constitutively active S – G2 
E2F  Constitutively active Cell cycle dependent? 
Cyclin B/CDK1 Cell cycle dependent – G2 Cell cycle dependent – G2 
CDKN1A Undetectable  Very low 
RB Cell cycle independent, 
hyperphosphorylated 
Cell cycle dependent 
Link between cell cycle duration and differentiation has been established in cancer cells, somatic cells, and 
adult stem cells.  As already described, cells in the G1 are particularly responsive to intracellular and extracellular 
signals based on which they decide their fate.  Therefore, it appears the G1 stage of the cell cycle is a period during 
which ES cells are most sensitive to differentiation, and the shortening of the G1 phase contributes to self-renewal.  
Indeed, it has been demonstrated that pharmacological activation of TTP53 followed by increased expression of 
CDKN1A leads to accumulation of cells in G1 phase of the cell cycle followed by human ES cell differentiation 
(Maimets et al., 2008). 
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1.8 DNA DAMAGE CHECKPOINT ACTIVATION 
1.8.1 Somatic cells 
Ionizing radiation induces a variety of DNA lesions (Goodhead, 1989; Hutchinson, 1985; Ward, 1988), including 
double and single strand breaks, as well as base damage, and, thus, evokes various cellular responses to DNA 
damage.  Double strand breaks (DSB) are particularly toxic for the cell and are more difficult to repair as they cause 
the loss of integrity of both DNA strands (Karagiannis and El-Osta, 2004).  Ionizing radiation-induced DNA damage 
activates checkpoint machinery in somatic cells and arrests the cell cycle allowing time for DNA repair to occur 
prior to proceeding to the next stage of the cell cycle. 
The upstream checkpoint components, including damage sensors and transducers, are shared by the G1/S, 
intra-S and G2/M checkpoints.  Two phosphoinositide 3-kinase like-kinase (PIKK) family members, ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and RAD3 related (ATR) protein kinases are central to 
initiation of DNA damage and replication checkpoints in response to various genotoxic stresses (Abraham, 2001).  
Activated ATM and ATR kinases phosphorylate numerous protein targets and transduce signals generated by DNA 
damage sensors to cell cycle stage specific effector proteins.  ATM exists as an inactive dimer that is 
autophosphorylated at serine 1981 in response to DNA double strand breaks (Bakkenist and Kastan, 2003).  
Activated ATM monomers localize primarily at DSB, where they phosphorylate many substrates, including TTP53 
(Banin et al., 1998; Canman et al., 1998), CHEK2 (Matsuoka et al., 2000; Melchionna et al., 2000), H2AX (Lukas et 
al., 2004), NBS1 (Gatei et al., 2000; Lim et al., 2000; Wu et al., 2000; Zhao et al., 2000), BRCA1 (Cortez et al., 
1999; Li et al., 2000).   
Checkpoint signal generated by ATM and ATR is transmitted to checkpoint kinases, CHEK1 and CHEK2 
that associate with DSB transiently and are released into the nucleus to transmit the signal throughout the nucleus 
(Lukas et al., 2003).  Although the ATR-CHEK1 pathway is predominantly activated in response to UV treatment 
(Guo et al., 2000), and ATM-CHEK2 is predominant in response to ionizing radiation (Melchionna et al., 2000), 
there is significant crosstalk between these two pathways, particularly as they share multiple targets (Shiloh, 2001; 
Zhou and Elledge, 2000).  Both CHEK1 and CHEK2 down-regulate CDC25 phosphatases (Falck et al., 2001; 
Furnari et al., 1999; Mailand et al., 2000) and activate TTP53 through phosphorylation (Hirao et al., 2000; Shieh et 
al., 2000).    
The tumor suppressor TTP53 plays a major role in multiple cellular processes occurring in response to 
DNA damage, including cell cycle arrest, apoptosis, and senescence.  It is constitutively expressed, but rapidly 
degraded due to MDM2 ubiquitination and targeting for proteasome degradation (Chehab et al., 1999).  ATM, ATR, 
CHEK2 and CHEK1, among other kinases, phosphorylate TTP53.  ATM (Banin et al., 1998; Canman et al., 1998) 
and ATR (Tibbetts et al., 1999) phosphorylate TTP53 at serine 15 which impairs MDM2 binding and enhances 
TTP53 accumulation and functional activation in response to DNA damage (Tibbetts et al., 1999).  CHEK2 and 
CHEK1 phosphorylate TTP53 at serine 20 (Hirao et al., 2000; Shieh et al., 2000) promoting its tetramerization, 




CDKN1A (p21) (el-Deiry et al., 1993), GADD45 and SFN (14-3-3-σ) (Hermeking et al., 1997), which play a role in 
the cell cycle arrest and other cellular responses to DNA damage summarized in Table 3.  
Table 3:  Tumor suppressor TP53 transcriptional target genes activated in response to DNA damage. 
DNA repair Cell cycle arrest Apoptosis Feedback regulation 
CDKN1A CDKN1A PUMA MDM2 
GADD45 SFN (14-3-3-σ) NOXA PIRH2 
p48 XP GADD45 BAX COP1 
 CDC25C TP53-AIP CCNG 
 Reprimo PIG3  
  FAS/APO1  
  KILLER/DR5  
Cell cycle progression is driven by temporal activation of cyclin/CDK complexes, making them logical 
targets of the checkpoint response.  The ionizing radiation induced DNA damage signaling and checkpoint 
activation is summarized in Scheme 8.  
 
Scheme 8:  Ionizing radiation induced checkpoint signaling. 
The main targets of the G1/S cell checkpoint are cyclin/CDK complexes that drive transition from G1 to the 
S phase of the cell cycle (Sherr, 1994).  Following ATM and CHEK2 activation, CDC25A phosphatase becomes 
phosphorylated and degraded (Arata et al., 2000; Mailand et al., 2000), rendering CDK2 inactive.  This event results 
in rapid initiation of the G1/S arrest because cyclin E/CDK2 complex is not activated and cannot phosphorylate RB 
and promote E2F release (Arata et al., 2000).  The G1/S arrest is sustained by TTP53 dependent CDKN1A 
expression and inactivation of CDK2 (Harper et al., 1993; Nyberg et al., 2002).  Therefore, ATM and CHEK2 
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dependent TTP53 activation is not required for cell cycle arrest initiation, but is required for the maintenance of this 
arrest. 
The main target of the G2/M cell cycle arrest is cyclin B/CDK1 complex that is essential for mitotic entry.  
This complex is kept inactive by CDK1 phosphorylation at inactivating sites (tyrosine 14 and 15), and depends on 
CDC25 phosphatases to remove these inhibitory phosphate groups.  CDC25C is phosphorylated by CHEK2 at serine 
216 which creates a binding site for an adaptor protein, SFN, resulting in nuclear exclusion and degradation of 
CDC25C-serine 216 (Furnari et al., 1999; Peng et al., 1997).  In addition, SFN affects nuclear localization of cyclin 
B/CDK1 (Giono and Manfredi, 2006).  Cyclin B/CDK1 complex has also been reported to be inhibited by CDKN1A 
and GADD45, aiding the maintenance of G2/M arrest (Bunz et al., 1998; Zhan et al., 1999).  Therefore, at least three 
TTP53 dependent genes, CDKN1A, SFN and GADD45, are involved in initiation and maintenance of G2/M cell 
cycle arrest. 
1.8.2 Embryonic stem cells 
Both mouse (Aladjem et al., 1998; Hong and Stambrook, 2004) and non-human primate (Fluckiger et al., 2006) ES 
cells have been reported to lack a functional DNA damage induced G1/S cell cycle arrest, and to be hypersensitive to 
DNA damaging agents, responding with high levels of apoptosis (Aladjem et al., 1998; Hong and Stambrook, 2004; 
Qin et al., 2007) and differentiation (Lin et al., 2005; Qin et al., 2007).  Furthermore, mouse ES cells may exhibit 
uncharacteristic localization and expression of checkpoint control proteins.  The DNA damage signaling factor 
Chek2 has been reported to localize aberrantly to the centrosomes in mouse ES cells and failed to translocate to the 
nucleus following irradiation (Hong and Stambrook, 2004).  Additionally, conflicting reports of TTP53 localization 
and activity have been described in mouse ES cells in response to DNA damage.  Aladjem et al. (Aladjem et al., 
1998) reported that mouse ES cells do not activate TTP53-dependent DNA damage responses and undergo TTP53-
independent apoptosis in response to ionizing radiation.  These authors and others have reported that TTP53 was 
inefficiently translocated to the nucleus after DNA damage in these cells (Aladjem et al., 1998; Chuykin et al., 2008; 
Hong and Stambrook, 2004).  In contrast, others have reported that treatment with DNA damaging agents results in 
TTP53 induced differentiation of mouse (Lin et al., 2005) and human (Qin et al., 2007) ES cells by suppressing 
NANOG expression through direct binding to the NANOG promoter, implying that TTP53 does successfully 
translocate to the nucleus after DNA damage.   
Wang and colleagues (Wang et al., 2009), examined S and G2/M checkpoint function in human embryonic 
carcinoma (EC) cells.  Human EC cells exhibited an S phase delay in response to irradiation, which has not been 
detected in mouse, primate or human embryonic stem cells.  Embryonic stem cells of different species all show 
tremendous sensitivity to DNA damage and undergo extensive cell death within hours of DNA damage.  However, 
human EC cells displayed higher survival following irradiation when compared to their differentiated counterparts.  
It is interesting to note these several differences between ES and EC cells given their numerous similarities and it 
will be illuminating to examine these two cell types further to better understand their similarities and differences.  
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1.9 DOUBLE STRAND BREAK REPAIR 
Double strands break are regarded as highly toxic for the cell because even one DSB can be potentially lethal (Rich 
et al., 2000).  Pathological DSB are generated by both exogenous agents (ionizing radiation, radiomimetic drugs, or 
topoisomerase poisons), as well as endogenous sources (reactive oxygen species (ROS) formed during metabolism, 
stalled replication forks, incorrect resolution during metabolic processing of DNA).  There are also physiological 
(intentional) DSB created during meiotic recombination or V(D)J recombination that would be as toxic as 
pathological DSB if not removed.  However, the predominant cause of DSB in proliferating cells is errors in DNA 
replication.  Given the toxicity of DSB for the cell, several repair pathways exist to remove them.  The two main 
pathways are non-homologous end joining (NHEJ) and homologous recombination (HR).   
Double strand breaks occur in various forms, such as blunt ends, 5’ and/or 3’ overhangs, and gaps, and may 
contain non-ligatable groups such as 3’-phosphate or 3’-phosphoglycolate groups, requiring processing before 
ligation (Friedberg Errol C, 2006).  NHEJ is an error-prone process that requires processing of DNA ends which 
may lead to loss of genetic information (Lees-Miller and Meek, 2003; Lieber et al., 2003).  Since it does not require 
the presence of the sister chromatid in the cell, it is present in all phases of the cell cycle, but is predominant during 
G1 and early S phases (Lee et al., 1997; Takata et al., 1998).  HR, however, depends on the presence of the sister 
chromatid and consequently is predominant in the late S and in G2 phases of the cell cycle when the duplicated 
chromatids are present (Haber, 2000; Rothkamm et al., 2003).   
The choice of the pathway depends on several factors, such as kinetics of repair, cell cycle stage, or cell 
type.  NHEJ and HR have rather different kinetics, with NHEJ being responsible for the fast mode of repair.  HR 
depends on the presence of sister chromatid in the cell. Consecutively, HR dominates in late S and G2, whereas 
NHEJ is preferred in G1 and early S (Takata et al., 1998).  Finally, the ability of particular cell type to tolerate 
mutations greatly affects the choice of DSB repair pathway.  Somatic cells may be more tolerant to inaccurate repair 
system such as NHEJ, which may be highly unbeneficial for the germ cells (during certain stages of 
spermatogenesis KU70/80 is not expressed). 
1.9.1 Non-homologous end joining 
Non-homologous end joining is error-prone because it involves processing of DNA ends which might lead to loss of 
nucleotides on both sides of the break (Mahaney et al., 2009).  Since it does not require template, it is a predominant 
way to repair DSB prior to S phase and is a major repair pathway in vertebrates (Branzei and Foiani, 2008; 
Rothkamm et al., 2003).  In addition, it has physiological role and is essential for V(D)J recombination in 
immunoglobulin genes; hence, mutations in genes that encode NHEJ proteins lead to severe combined 
immunodeficiency phenotype (SCID) and increased radiosensitivity.   
The first step of NHEJ is recognition of and binding to DNA ends by XRCC6 (KU70)/XRCC5 (KU80) 
heterodimer (KU70/80) which occurs within seconds of break formation.  KU70/80 represents the most abundant 
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end-binding factor in eukaryotes.  The complex can accommodate variety of end structures, such as blunt ends, 5’ 
and 3’ overhangs, or covalently closed hairpins, in sequence-independent manner.  KU70/80 is essential for 
recruitment of other NHEJ proteins to the DSB in vivo (Mahajan et al., 2002; Mari et al., 2006; Uematsu et al., 
2007; Yano et al., 2008).  DNA dependent protein kinase catalytic subunit (PRKDC) is a member of PIKK family 
(together with ATM and ATR), and is the first to be recruited to DSB by KU70/80 (Uematsu et al., 2007).  DNA 
structure is important factor for DNA-PK activation, with DSB being the most effective activators irrespective of 
DNA sequence.  Without DNA, KU70/80 and PRKDC interaction is not strong (Gottlieb and Jackson, 1993; Suwa 
et al., 1994).  Together PRKDC and KU70/80 form DNA-PK complex which tethers the ends and protects them 
from nuclease attack.  Among the DNA-PK targets are NHEJ proteins such as XRCC6, XRCC5 (Douglas et al., 
2005), XRCC4 (Yu et al., 2003), DCLRE1C (ARTEMIS) (Ma et al., 2005a), and ligase IV (Wang et al., 2004), but 
their phosphorylation does not appear to be required for NHEJ in vivo.  The best candidate for DNA-PK appears to 
be PRKDC which is autophosphorylated at numerous sites.  This event appears to have role in regulating PRKDC 
enzymatic function and dissociation of phosphorylated PRKDC from DNA bound KU70/80 (Chan and Lees-Miller, 
1996; Ding et al., 2003; Merkle et al., 2002).  The next step in NHEJ is processing of DNA ends.  Irradiation 
induced DSB often contain non-ligatable end groups and/or other DNA lesions and can be very complex requiring 
end processing.  As mentioned earlier, NHEJ operates in the absence of the sister chromatid or regions of 
microhomology that could serve as template, and can lead to loss of genetic information (Budman and Chu, 2005).  
The main candidate for end processing is ARTEMIS.  ARTEMIS is a 5’→3’ exonuclease that in the presence of 
PRKDC and ATP attains endonuclease activity toward double strand DNA to single strand DNA transitions and 
DNA hairpins (Ma et al., 2002; Ma et al., 2005b).  ARTEMIS can process DNA ends until they are compatible 
(removal of 5’ and trimming of 3’ overhangs), so at least for some NHEJ events polymerase may not be necessary.  
However, because radiation induced breaks can be very complex and require further processing leading to formation 
of DNA gaps, the following steps may include extension by terminal deoxyribonucleotidetransferase (DNTT) 
(Chappell et al., 2002; Karimi-Busheri et al., 2007), or polymerase λ or μ (Bertocci et al., 2006; Davis et al., 2008; 
Paull, 2005).  Lastly, KU70/80 recruits and loads XRCC4-ligase IV functional complex that ligates DNA termini 
(Grawunder et al., 1997; Grawunder et al., 1998; Mari et al., 2006). 
1.9.2 Homologous recombination 
Homologous recombination serves several biological functions such as crossover generation during meiosis, 
telomerase maintenance, preservation of stalled replication forks, as well as DSB repair (San Filippo et al., 2008).  
There are several distinct mechanisms of HR that participate in the abovementioned processes (Table 4), but I will 
focus on double strand break repair and synthesis dependent strand annealing, as these two pathways are typically 
associated with DSB repair. 
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Table 4:  Homologous recombination pathways (San Filippo et al., 2008). 
Pathway Biological role Products 
Double strand break repair 
(DSBR) 
Meiotic recombination 
Double strand break repair Crossovers and noncrossovers 
Synthesis dependent strand 
annealing (SDSA) 
Double strand break repair 
Meiotic recombination Only noncrossovers 
Single strand annealing (SSA) 
Repair of breaks within repetitive 
sequences 
Deletion of one direct repeat and 
nucleotide sequence between repeats 
Break induced replication (BIR) 
Repair when there is only one DSB 
end – telomere elongation, 
replication fork restart 
Accurate repair if sister chromatid or 
homologous chromosome are used, 
non-reciprocal translocation if repeat 
sequence on non-homologous 
chromosomes is used 
Homologous recombination DSB repair is critically dependent on the presence of the extensive regions of 
homology and repairs DSB using the information present on the undamaged sister chromatid.  Use of homologous 
chromosome as a template (such as in G1 when sister chromatid is not present) can lead to loss-of heterozygosity, 
which can be even more deleterious than error-prone NHEJ; thus, HR mediated DSB repair occurs when an identical 
DNA molecule is present in the cell (late S and G2 phase)(San Filippo et al., 2008).   
The first step of HR repair is conversion of broken DNA ends into HR substrates, which involves 
degradation of 5’ ends leaving 3’ overhang several hundred bases long (Scheme 9).  The candidate for 
exonucleolytic cleavage is the MRE11/RAD50/NBS1 (MRN) complex (Paull and Gellert, 1998; Paull and Gellert, 
1999).  The MRN complex has been shown to participate in virtually all aspects of DNA end metabolism – DSB 
detection (Mirzoeva and Petrini, 2001), DSB processing (Lewis et al., 2004), HR and meiosis (Bressan et al., 1999), 
telomere maintenance (Boulton and Jackson, 1998; Kironmai and Muniyappa, 1997), and cell cycle checkpoint 
activation (Carney et al., 1998; Zhao et al., 2000).  Upon resection, single-stranded DNA (ssDNA) ends are bound 
by replication protein A (RPA), which assists in removal of secondary structures that would inhibit the following 
steps.  However, precoating of ssDNA with RPA prevents binding of the RAD51 recombinase.  The loading of 
RAD51 is supported by RAD52, a DNA-binding protein that facilitates interaction of RAD51 with ssDNA in the 
presence of RPA, and counteracts an otherwise inhibitory effect of RPA (Sung, 1997).  RAD51 binding to DNA 
induces extensive stretching and unwinding of B-DNA leading to presynaptic filament formation that assists 
homologous strand pairing (Sung and Robberson, 1995).  Next, during synapsis, heteroduplex DNA is formed 
between invading strand coated with RAD51 and template DNA molecule by homologous pairing leading to strand 
displacement.  At this stage RAD52 promotes the annealing of complementary ssDNA strands.  Once heteoduplex is 
formed it can be extended by branch migration.  RPA coats displaced strand preventing re-annealing and thus 
accelerate branch migration.  Branch migration is inefficient with RAD51 alone, but is greatly approved by the 
cofactors, such as RPA and RAD52 (Baumann et al., 1996; Baumann and West, 1999; Benson et al., 1998; Gupta et 
al., 1997; Sung and Robberson, 1995; Van Dyck et al., 1998).  The 3’ end of the invading strand primes DNA 
synthesis using the sister chromatid as a template.   Capture of the second DSB end leads to formation of an 
intermediate with two Holliday junctions (cruciform DNA structure formed by crossing of the invading strand and 
displaced strand).  Finally, the Holliday junctions are resolved by specialized endonucleases giving rise to crossover 
or noncrossover depending on whether all four strands are cut (Scheme 9:  two dark and two light blue arrows; 
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crossover) or the invading and displaced strand (light blue arrows; noncrossover) (Sugawara et al., 2003; Szostak et 
al., 1983; Wolner et al., 2003). 
 
Scheme 9:  Double strand break repair by homologous recombination. 
Unlike meiotic HR, homologous recombination DSB repair rarely leads to formation of crossovers and 
hence another model, synthesis dependent strand annealing, was proposed to account for data on mitotic HR 
(Ferguson and Holloman, 1996; Nassif et al., 1994; Strathern et al., 1982).  In this model, following strand invasion 
and repair DNA synthesis, second DSB end is not captured, and an intermediate with two Holiday junctions is not 
formed.  Instead, the branch migration proceeds until complete displacement of the invading strand is achieved, so 
that it anneals with the second resected DSB end.  Now, the DNA synthesis fills in the gap on the second resected 
DSB end, whereas the displaced strand reanneals with its complimentary strand forming intact template DNA 
molecule. 
HR may be enhanced when NHEJ is defective, suggesting that KU70/80 binding to DNA ends may 
interfere with HR (Fukushima et al., 2001; Pierce et al., 2001), and some even suggest that in mammalian cells 
KU70/80 and RAD52 compete for binding to broken DNA ends.  However, experiments with XRCC4/ligase IV 
mutants demonstrated that in the absence of functional NHEJ homologous recombination is stimulated, suggesting 
that 1) NHEJ might be the primary pathway for DSB repair, and 2) that if NHEJ fails, HR might take over (Delacote 
et al., 2002; Frank-Vaillant and Marcand, 2002). 
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1.9.3 Embryonic stem cells 
It has been suggested that mouse ES cells rely mainly on HR to fix DSB because they spend most of their cell cycle 
time in S phase of the cell cycle when the sister chromatid is present, as well as in order to prevent accumulation and 
subsequent propagation of genetic changes.  In support of this hypothesis, Rad51 knock out mouse embryos exhibit 
profound radiosensitivity and die early in development due to decreased proliferation and massive chromosome loss 
(Tsuzuki et al., 1996).  Rad51 null ES cells cannot be isolated from knock out mouse embryos, nor generated in 
vitro (Lim and Hasty, 1996).  A TTP53 null background only partially improves the phenotype of Rad51 deficient 
mouse embryos, as double knock-outs exhibit extended development, but still die once accumulated DNA damage 
interferes with normal cellular function and mitosis (Lim and Hasty, 1996).  Similarly, complete loss of Rad50, 
Nbs1 and Mre11 is early embryonic lethal, suggesting that the MRN complex is required for normal cellular 
function, proliferation, and growth.  Mre11 knock out ES cells cannot be obtained (Xiao and Weaver, 1997), Nbs1 
deficient ICM fail to proliferate and die in vitro (Zhu et al., 2001), whereas early Rad50 null mouse ES cells are 
hypersensitive to ionizing radiation and cannot be propagated in cell culture (Luo et al., 1999), indicating that 
mutations in these genes are toxic at the cellular level.   
Rad52 knock-out mice are viable and show no impaired viability, fertility, or immune system deficiency.  
Mouse Rad52 nullizygous ES cells do not show signs of radiosensitivity, and exhibit 30-40% reduction in 
homologous recombination, unlike yeast mutant RAD52– cells which are not viable (Rijkers et al., 1998). This 
suggests that there are functionally related genes in mammalian cells that can compensate the absence of RAD52.  
Rad54 inactivation in mouse ES cells leads to decreased homologous recombination and increased radiosensitivity, 
but Rad54 null mice are viable and fertile (Essers et al., 1997), suggesting that Rad54 is not essential for normal 
mouse development.  
Mice missing any of the genes involved in NHEJ are viable, or die only late in embryonic development.  
Nullizygous Lig4 and Xrcc4 mice are late embryonic lethal due to massive TTP53 dependent neuronal apoptosis, 
arrested lymphogenesis, and other cellular defects (Barnes et al., 1998; Frank et al., 2000; Li et al., 1995). In this 
case a TTP53 null background rescues embryonic lethality, but not lymphocyte development or radiosensitivity.  
Xrcc6 or Xrcc5 inactivation in mice results in growth retardation, profound immunodeficiency, as well as marked 
radiosensitivity and inability to perform end-joining at the cellular level (Gao et al., 1998; Gu et al., 1997; Jin et al., 
1998; Nussenzweig et al., 1997).  Mice lacking Prkdc are immunodeficient, but do not exhibit growth retardation 
(Gao et al., 1998).   
Mouse ES cells that lack Prkdc do not exhibit increased radiosensitivity or sensitivity to etoposide 
treatment, unlike Prkdc knock out fibroblasts (Gao et al., 1998; Jin et al., 1998), suggesting that NHEJ is not a 
predominant DSB repair pathway in ES cells.  In addition, wild type mouse ES cells express low levels of Prkdc, 
corresponding to lower activity of DNA-PK in these cells in comparison to mouse embryonic fibroblasts (MEF).  
Furthermore, mouse ES cells express a 20 fold higher level of Rad51 in comparison to MEF, and about the same 
level of Xrcc4 (Tichy and Stambrook, 2008).   
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Important insight into role of homologous recombination and non-homologous end joining came from 
studies by Banuelos et al. (Banuelos et al., 2008) in wild type and Atm, H2ax, and Prkdc mutant mouse ES cells. 
H2ax knockout mice exhibit similarities to Atm null mice, including radiosensitivity, growth retardation, and 
chromosomal abnormalities (Celeste et al., 2002; Xu et al., 1996).  Mouse ES cells that lack H2ax are highly 
sensitive to ionizing radiation and radiomimetic drug treatments,  show increased spontaneous and irradiation 
induced chromosomal abnormalities, and a subtle reduction in size of Rad51 foci following ionizing radiation 
exposure (Bassing et al., 2002).  Mouse ES cells defective in Atm or H2ax exhibit faster DSB repair in comparison 
to wild type mouse ES cells, decreased survival, and inability to form foci of phosphorylated Atm (although Atm is 
autophosphorylated).  In addition, cells that do not have Atm or H2ax express higher level of Prkdc than wild type 
mouse ES cells.  Inhibition of DNA-PK activity resulted in reduced DSB rejoining in H2ax knock-out, but not wild 
type mouse ES cells, suggesting that DNA-PK has an important role in DSB repair in H2ax deficient mouse ES 
cells.  However, in wild type mouse ES cells Prkdc activity still contributes to their survival following irradiation, 
because inhibition of Prkdc with its specific inhibitor NU7026 reduces survival of wild type and H2ax mutant mouse 
ES cells.  Taken together, it appears that DNA-PK dependent DNA repair is not the main pathway for repair of 
DSB, but still contributes to survival of mouse ES cells following DNA damage.  In instances when homologous 
recombination is impaired, mouse ES cells can redirect DSB repair toward NHEJ. 
Both mouse (Saretzki et al., 2004) and human (Maynard et al., 2008) ES cells exhibit increased capacity for 
DNA damage removal following various genotoxic treatments, including DSB removal after ionizing radiation in 
comparison to differentiated cells.  During differentiation of mouse (Saretzki et al., 2004) and human (Saretzki et al., 
2008) ES cells expression of antioxidant and DNA repair genes is reduced, while the frequency of γ-H2AX positive 
cells increases. Wild type human ES cells express higher level of PRKDC and XRCC6 relative to mouse ES cells 
and more similar level to differentiated human cells (Banuelos et al., 2008).  Interestingly, there is a general 
difference between mouse and human somatic cells in their dependence on NHEJ.  For example, DNA-PK activity 
(Finnie et al., 1995) and XRCC6 expression (Anderson and Lees-Miller, 1992) are higher in human relative to 
mouse somatic cells, and XRCC5 is an essential protein in human, but not mouse cells (Li et al., 2002).  In addition, 
human ES cells rejoin DSB faster than mouse ES cells (Banuelos et al., 2008) suggesting there might be difference 
between mouse and human ES cells’ choice or repair pathway. 
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2.0  MATERIAL AND METHODS 
2.1 CELL CULTURE AND DRUG TREATMENTS 
2.1.1 Human ES cell culture on feeder cells 
Human ES cell lines WA07 and WA09 (WiCellTM, Madison, WI) were cultured in human ES cell medium 
containing 80% knock-out Dulbecco's Modified Eagle Medium (DMEM), 20% knock-out serum replacer, 1% non-
essential amino acids, 1% penicillin/streptomycin (100U/100 μg/ml), 2 mM l-glutamine and 4 ng/ml basic fibroblast 
growth factor (FGF2; all from Invitrogen, Carlsbad, CA) on mitomycin C-treated mouse embryonic fibroblasts 
(MEF; Millipore Corporation, Billerica, MA).  Cells were passaged manually every seven days and medium was 
changed every 48 hours.  Cells were routinely tested for normal karyotype as previously described (Navara et al., 
2007). 
2.1.2 Human ES cell culture on MatrigelTM 
For flow cytometry experiments human ES cells were plated on BD Matrigel™ human ES cell qualified Matrix (BD 
Bioscience, Bedford, MA), grown in human ES medium conditioned with feeder cells for 24 hours, and 
supplemented with an additional 4 ng/ml FGF2.  For sister chromatid exchange assay and gene expression studies 
human ES cells were plated on Matrigel™ and grown in mTeSRTM1 medium (StemCell Technologies, Vancouver, 
BC, Canada) supplemented with 1% penicillin/streptomycin (100U/100 μg/ml). 
2.1.3 Human induced pluripotent stem cell culture 
Human iPS(IMR-90)-1 cells were obtained from WiCellTM and amniotic epithelim (AE) iPS cell line was derived in 
our laboratory buy transduction of AE primary cells with lentiviral vector carrying OCT4, SOX2, KLF4 and MYC.  
Both iPS cell lines were grown on BD Matrigel™ human ES cell qualified Matrix in mTeSRTM1 medium 
supplemented with 1% penicillin/streptomycin (100U/100 μg/ml).  Medium was changed every 24 hours and cells 
were passaged every 5 – 6 days using 1 mg/ml dispase (StemCell Technologies).   
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2.1.4 IMR-90 cell culture 
IMR-90 human diploid fibroblast strain was obtained from American Type Culture Collection (ATCC; Manassas, 
VA).  IMR-90 fibroblasts were derived from the 16 week old female fetus.  Cells were grown in Eagle’s Minimum 
Essential Medium (ATCC), supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin 
(100U/100 μg/ml), and passaged every 5 – 6 days using TrypLETM (Invitrogen).  Medium was removed, cells 
washed once with phosphate buffered saline (PBS) to remove any traces of serum, and TrypLETM was added for five 
minutes at 37oC.  TrypLETM was neutralized with serum containing cell growth medium, and cells were transferred 
to a new flask 
2.1.5 Teratoma fibroblast cell culture 
WA07 derived teratoma fibroblasts (H7TF) were isolated from a teratoma obtained from mice injected with 
WA07p69 cells.  Following tumor growth, teratoma was isolated and tissue enzymatically dissociated into single 
cell suspension.  Teratoma fibroblasts were grown in Dulbecco's Modified Eagle Medium (DMEM), 10% fetal 
bovine serum, 1% non-essential amino acids, 1% penicillin/streptomycin (100U/100 μg/ml), 2 mM l-glutamine (all 
from Invitrogen), and passaged every 4 – 5 days using TrypLETM as described for IMR-90 cells (2.1.4). 
2.2 DRUG TREATMENTS 
2.2.1  KU55933 treatment 
For ATM inhibition studies, cells were treated with 10 μM, 50 μM, or 100 μM KU55933 (generously provided by 
Graeme Smith, Astra Zeneca), or vehicle dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO) one hour prior to γ-
radiation treatment.  
2.2.2 BrdU and camptothecin treatment 
For sister chromatid exchange studies, human ES cells were grown on Matrigel™ as previously described.  Four 
days after plating 10 μM 5-bromo-2’-deoxy-uridine (BrdU; Roche Applied Science, Mannheim, Germany) was 
added to the human ES cell medium.  Following twenty four hours incubation, BrdU containing medium was 
aspirated, cells washed three times with phosphate-buffered saline (PBS; Invitrogen), and medium containing 100 
nM camptothecin (Sigma) was added.  One hour following addition of camptothecin, cells were washed three times 
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with PBS and incubated for 15 hours in fresh medium.  In order to arrest mitotic cells 120 ng/ml colcemid 
(Invitrogen) was added to the medium for 90 minutes.   Following colcemid treatment, cells were harvested for 
cytogenetic preparation (2.5). 
2.3 IRRADIATION 
Human ES cells were irradiated four to seven days after passaging with two grays of γ-radiation using a 
Gammacell® 1000 Elite cesium137 irradiator (Nordion, Ottawa, Canada).  Immediately after irradiation cells were 
returned to the incubator for recovery until the appropriate time point.  
2.4 IMMUNOCYTOCHEMISTRY AND CONFOCAL MICROSCOPY 
For immunocytochemistry human ES cells were grown on Thermanox® plastic coverslips (NUNCTM, Rochester, 
NY) on MEF feeder cells, fixed in 2% formaldehyde, and permeabilized in 0.1% Triton X-100 in tris-buffered saline 
(TBS; both Sigma).  Incubation with the primary antibodies listed in Table 5 was carried out in a humidified 
chamber at 37°C for 45 minutes.  Primary antibodies were detected using species-specific fluorescently labeled 
secondary antibodies (Invitrogen) at 37°C for 45 minutes.  DNA was visualized by addition of 1 μM Toto-3 
(Invitrogen).  Coverslips were mounted onto glass slides with Vectashield anti-fade mounting medium containing 
DAPI (Vector Laboratories, Burlingame, CA).  Slides were examined using a Leica TCS-SP2 laser scanning 
confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany).  The appropriate species-specific secondary 
antibody controls were obtained in the same manner, but incubation with primary antibodies was omitted.  Co-
localization of immunocytochemical probes was determined using ImageJ software (Rasband, 1997-2008).  For the 
analysis of mitotic figure morphology the following criterion was used: mitotic figures that displayed misaligned 
chromosomes in metaphase, lagging chromosomes in anaphase, or multipolar spindles were regarded as aberrant.  
Prophase cells were considered as non-informative, and were not categorized as either normal or aberrant.  
Examples of normal and aberrant mitotic figures are shown in the Figure 10D. 
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Table 5:  List of primary antibodies used for immunocytochemistry. 
Antigen Manufacturer (catalogue number) Dilution 
OCT4 Santa Cruz Biotechnology, Inc., Santa Cruz, CA (sc-5279) 1:100 
NANOG R&D Systems, Inc., Minneapolis, MN (AF1997) 1:50 
SSEA4 Developmental Studies Hybridoma Bank, The University of Iowa, IA (clone 
MC-813) 
1:5 
ATM-serine 1981 Epitomics, Burlingame, CA (EP1981) 1:100 
CHEK2-threonine 68 Cell Signaling Technology, Danvers, MA (2661) 1:100 
TTP53-serine 15 Cell Signaling Technology, Danvers, MA (9284) 1:100 
TTP53-serine15 Cell Signaling Technology, Danvers, MA (9286) 1:100 
Histone H3-serine 10 Cell Signaling Technology, Danvers, MA (9701) 1:100 
γ-H2AX Upstate, Lake Placid, NY (05-636) 1:200 
RAD51 EMD4Biosciences, Gibbstown, NJ (PC130) 1:200 
β-tubulin Developmental Studies Hybridoma Bank, The University of Iowa, IA (E7) 1:5 
2.5 CELL HARVESTING  
Human ES cells grown on feeders were manually scraped and transferred to a clean tube.  Human ES and iPS cells 
grown on Matrigel™ were harvested with accutase (Chemicon International, Temecula, CA).  Medium was 
removed, cells washed with PBS once, and treated with accutase for two minutes at 37oC.  Detached cells were 
transferred to a clean tube; dish was rinsed with PBS and scraped with cell scraper to detach any remaining cells.  
Human fibroblasts (IMR-90 and WA07p69 teratoma fibroblasts) were collected using TrypLETM (2.1.4).  
2.6 RNA EXTRACTION, REVERSE TRANSCRIPTION, TAQMAN LOW DENSITY ARRAYS, 
PCR ARRAYS 
2.6.1 RNA extraction and DNA clean-up 
Collected cells were pelleted by centrifugation, and lysed with 1ml of TRIzol ® Reagent (Invitrogen).  The lysate 
was homogenized and 0.2ml of chloroform (Sigma) was added.  Phase separation was achieved by centrifugation at 
2500xg for five minutes, and aqueous phase was transferred into clean tube.  RNA was precipitated with 0.6ml 
isopropyl alcohol (Sigma) overnight at -20oC.  Following centrifugation at 16,000xg for 30 minutes at 4oC on the 
next day, RNA pellet was washed with 70% ethanol (Sigma), air dried and redissolved in RNase-free water.  
Purified RNA was subjected to DNA clean up with the DNA-freeTM kit (Ambion, Austin, TX).  One tenth of the 
sample volume of the DNase I buffer and two microliters of rDNase I were added to the samples, mixed gently and 
incubated at 37°C for 30 minutes.  The DNase reaction was stopped by addition of one tenth of the total volume of 
DNase I inactivation reagent, and samples were incubated for two minutes at room temperature.  Samples were 
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centrifuged at 9500xg and clear supernatant containing purified RNA transferred to clean tube.  Concentration and 
quality of the samples were determined by UV spectrophotometry using Eppendorf Biophotometer (Hamburg, 
Germany).  RNA samples of A260/280 in range of 1.8 – 2.0 were used for further experimentation. 
2.6.2 Reverse transcription and TaqMan® Low Density Arrays 
Complementary DNA was produced using High Capacity cDNA RT kit (Applied Biosystems, Foster City, CA).  
Two micrograms of total RNA were used per reverse transcription reaction which composition is represented in 
Table 6.   
Table 6:  Reverse transcription reaction mixture. 
Component Volume/ Reaction [μl] 
10X RT buffer 2.0 
25X dNTP mix (100 mM) 0.8 
10X RT random primers  2.0 
MultiScribeTM reverse transcriptase 1.0 
RNase inhibitor 1.0 
2μg RNA concentration dependent 
Nuclease free water up to 20μl final reaction volume 
Reverse transcription was carried out in thermal cycler with the following conditions: 25oC for 10 minutes, 
37oC for 120 minutes, and 85oC for five seconds.  The TaqMan® Human Stem Cell Pluripotency Array (Applied 
Biosystems) was used following manufacturer’s instructions.  Briefly, 10μl of cDNA reaction product was mixed 
with 40μl of nuclease free water and 50μl of 2X TaqMan® Universal PCR Master Mix (Applied Biosystems).  The 
mixture was loaded into array with preloaded TaqMan® gene expression assays, and quantitative PCR reaction 
carried out on Applied Biosystems 7900HT system under following conditions: 50oC for two minutes, 95oC for 10 
minutes, and 40 cycles of 95oC followed by 60oC for one minute.  Data for NANOG, POU5F1 and CD9 expression 
were analyzed using SDS 2.2.2. software (Applied Biosystems).  Expression fold changes were calculated using the 
-ΔΔCt method and normalized using ACTB as the endogenous control.   
2.6.3 Reverse transcription and PCR Arrays 
Complementary DNA was produced using RT2 First Strand Kit (SA Biosciences, Frederick, MD).  First step was to 
perform genomic DNA elimination reaction followed by first strand cDNA synthesis reaction following 
manufacturer’s directions.  One microgram of total RNA was mixed with 5X genomic DNA elimination buffer, and 
nuclease free water was added to adjust final volume to 10μl.  The genomic DNA elimination mixture was incubated 
at 42oC for five minutes and transferred to ice for at least one minute.  The composition of the subsequent reverse 
transcription reaction is represented in Table 7.  The first strand synthesis reaction was carried out at 42oC for 15 
minutes and immediately stopped by heating to 95oC for five minutes.  Finally, 91μl of nuclease free water were 
added to each cDNA synthesis reaction.   
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Table 7:  Reverse transcription reaction mixture. 
Component Volume/ Reaction [μl] 
5X RT buffer 3 4 
Primer and external control mix 1 
RT enzyme mix 3  2 
Genomic DNA elimination mixture 10 
Nuclease free water 3 
DNA Damage Signaling Pathway PCR array (SA Biosciences) was used according to manufacturer’s 
directions.  The quantitative PCR reaction mixture is represented in Table 8.  The PCR was carried out using the 
following program on Applied Biosystems 7900HT system: 10 minutes at 95oC to activate HotStart DNA 
polymerase, followed by 40 cycles of 95oC for 15 seconds and 60oC for one minute. 
Table 8:  Quantitative PCR reaction mixture. 
Component Volume/ Reaction [μl] 
2X SABioscienced RT2 qPCR Master Mix 2000 
Diluted reverse transcription reaction product 102 
Nuclease free water 1898 
The PCR array contains predispensed primer sets that in addition to 84 DNA damage signaling pathway 
genes include five housekeeping genes for normalization of PCR array data, one genomic DNA contamination 
control, three reverse transcription controls, and three PCR positive controls.  Data were analyzed using SDS 2.2.2. 
software and expression fold changes were calculated using the -ΔΔCt method and normalized using ACTB as the 
endogenous control.   
2.7 WESTERN BLOT 
Human ES cells grown on feeders, human ES and iPS cells grown on Matrigel™, and IMR-90 and WA07p69 
teratoma fibroblasts were harvested as described in 2.5.  Collected cells were pelleted by centrifugation, washed 
once in PBS, and lysed in RIPA buffer supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF; both 
Sigma) and 2X HaltTM phosphatase inhibitor cocktail (Pierce, Rockford, IL).  The protein concentration was 
determined using bicinchoninic acid (BCA) assay (Bio-RAD Laboratories, Inc., Hercules, CA) and 5μg of protein 
were loaded per well.  Proteins were separated by SDS-polyacrylamide gel electrophoresis using 4-15% or 4-20% 
Ready Gel Tris-HCl gels (Bio-RAD Laboratories) at 200 V constant, 120 mA in 25 mM tris, 192 mM Glycine, and 
0.1% (w/v) SDS pH 8.3 running buffer, followed by transfer to BioTraceTM PVDF membrane (Pall Life Sciences, 
East Hills, NY) at 100 V, 350 mA in 25 mM tris, 192 mM glycine, and 20% (v/v) methanol for one hour.  Proteins 
with higher molecular weight (ATM) were separated using 3-8% NuPAGE® Tris-Acetate® gels (Invitrogen) at 150 
V constant, 110 mA in Novex® tris-acetate SDS running buffer (Invitrogen), followed by overnight transfer at 30 V, 
90 mA in 25 mM tris, 192 mM glycine, and 20% (v/v) methanol.  The membrane was blocked in TBS with 5% milk 
and 0.1% Tween-20 (all from Sigma) for one hour at room temperature.  Membranes were incubated with the 
primary antibodies listed in Table 9 diluted in the blocking solution at 4°C overnight.  The next day three washes in 
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the blocking solution were done and primary antibodies were detected using horse radish peroxidase (HRP)-
conjugated species-specific secondary antibodies (Invitrogen) diluted in blocking buffer and incubated for one hour 
at room temperature.  Following three washes in TBS with 0.1% Tween-20, detection of bound antibodies was 
performed with ECL AdvanceTM Western Blotting Detection kit (Amersham Biosciences, Piscataway NJ).  
Chemiluminescent signals were recorded using HyperfilmTM (Amersham Biosciences). 
Table 9:  List of primary antibodies used for Western blot analysis. 
Antigen Manufacturer (catalogue number) Dilution 
OCT4 Santa Cruz Biotechnology, Inc., Santa Cruz, CA (sc-5279) 1:1000 
NANOG Kamiya Biomedical Company, Seattle, WA (PC-102) 1:500 
Cleaved Caspase-3 Cell Signaling Technology, Danvers, MA (9661) 1:500 
ATM Sigma, St. Louis, MO (MAT3-4G10/8) 1:10,000 
ATM-serine 1981 Epitomics, Burlingame, CA (EP1890Y) 1:1000 
CHEK2 Thermo Fisher Scientific, Fremont, CA (MS-1515) 1:500 
CHEK2-threonine 68 Cell Signaling Technology, Danvers, MA (2661) 1:500 
TTP53 Santa Cruz Biotechnology, Inc., Santa Cruz, CA (sc-6243) 1:500 
TTP53-serine 15 Cell Signaling Technology, Danvers, MA (9284) 1:500 
TTP53-serine20 Cell Signaling Technology, Danvers, MA (9287) 1:500 
NBS1 Epitomics, Burlingame, CA (Y112) 1:500 
NBS1-serine343 Cell Signaling Technology, Danvers, MA (3001) 1:500 
RAD50 GeneTex, Inc., Irvine, CA (GTX70228) 1:500 
MRE11 Novus Biologicals, Inc, Littleton, CO (NB100-473) 1:500 
RAD51 Thermo Fisher Scientific, Fremont, CA (MS-988) 1:200 
RAD52 GeneTex, Inc., Irvine, CA (GTX70301) 1:500 
Ligase IV GeneTex, Inc., Irvine, CA (GTX30740) 1:800 
XRCC4 GeneTex, Inc., Irvine, CA (GTX70293) 1:750 
RB-serine 780 Cell Signaling Technology, Danvers, MA (9307) 1:750 
RB-serine 795 Cell Signaling Technology, Danvers, MA (9301) 1:750 
RB-serine 897/811 Cell Signaling Technology, Danvers, MA (9308) 1:750 
CDKN1A Cell Signaling Technology, Danvers, MA (2946) 1:200 
α-tubulin Sigma, St. Louis, MO (T 5168) 1:10,000 
2.8 FLOW CYTOMETRIC ANALYSIS  
2.8.1 Analysis of cell cycle distribution 
Cell cycle analysis by flow cytometry was performed using propidium iodide (PI; BD Biosciences Pharmingen, San 
Diego, CA).  Human ES cells grown on Matrigel™ were harvested using accutase as described in 2.5, pelleted and 
washed in PBS.  Five hundred thousand cells were resuspended in 1ml of PBS, fixed by addition of ice-cold 70% 
ethanol drop wise, and placed at -20°C overnight.  Following fixation, cells were washed with PBS, and centrifuged 
at 200xg for five minutes.  The cell pellet was resuspended in PBS solution containing PI (5 μg/106 cells) and RNase 
(Sigma; 10 mg/ml), and incubated in the dark at room temperature for 30 minutes.  Cells were examined using a 
Becton Dickinson FACSVantage DiVa (BD, Franklin Lakes, NJ), and DNA-PI-A histograms were analyzed using 
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ModFit (Verity Software House, Topsham, ME).  Results were gated to exclude cellular debris, sub G0 population, 
and doublets. 
2.8.2 EdU pulse chase incorporation 
Human ES cells grown on Matrigel™-coated plates were labeled with 10 μM 5-ethynyl-2’-deoxyuridine (EdU; 
Invitrogen) for 30 minutes (pulse) before replacing with fresh medium.  Human ES cells were immediately collected 
(non-irradiated control cells), or irradiated with two grays, and left to recover for 4, 8, 16 and 24 hours post 
irradiation (chase).  Cells were harvested with accutase as described in 2.5.  Cell fixation, permeabilization and EdU 
detection were performed following manufacturer’s instructions for Click-iTTM EdU flow cytometry kit (Invitrogen).  
Following harvesting, five hundred thousand human ES cells were washed in 1% bovine serum albumin (BSA, 
Sigma) in PBS and centrifuged at 200xg for five minutes.  Supernatant was discarded, cell pellet resuspended in 
300μl of 4% paraformaldehyde in PBS, and incubated in dark at room temperature for 15 minutes.  Following 
centrifugation and wash in 1% BSA in PBS, cell pellet was resuspended in 1X saponin solution containing 1% BSA 
in PBS and incubated in dark at room temperature for 15 minutes.  Human ES cells were pelleted and stained with 
500μl of the reaction cocktail whose composition is presented in Table 10, in dark at room temperature for 30 
minutes.   
Table 10:  Click-iT reaction cocktail composition. 
Component Volume/ Reaction [μl] 
1X Click-iTTM reaction buffer 438 
100 mM CuSO4 10 
10X Click-iTTM reaction buffer additive 5 
Alexa Fluor® 647 azide (dye) 2.5 
Water 44.5 
 
After staining, 1% BSA in PBS was added to the reaction mixture to wash away the excess of unbound dye, 
and cells were centrifuged at 200xg for five minutes.  The cell pellet was resuspended in PBS solution containing PI 
(5 μg/106 cells) and RNase (10 mg/ml), and incubated at room temperature in the dark for 30 minutes.  Appropriate 
compensation tubes were used to set up the flow cytometer – unstained cells, cells stained with PI only (no dye), 
cells stained with dye only (no PI), as well as cells that were not incubated with EdU and were stained with both PI 
and dye.  Human ES cells were analyzed using a Becton Dickinson FACSVantage DiVa.  Dot plots representing 
EdU-647 fluorescence against DNA content were analyzed using BD FACSDiva software 6.1.1. (BD Biosciences, 
San Jose, CA). 
2.8.3 Annexin V labeling 
Human ES cells were grown on Matrigel™ and harvested by manual scraping in PBS eight hours after exposure to 
two grays of γ-irradiation.  Staining with Annexin V and PI was performed according to manufacturer’s instructions 
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for Annexin V-FITC Apoptosis Detection Kit I (BD Pharmingen).  Briefly, harvested cells were centrifuged at 
200xg for five minutes and washed twice with cold PBS, and then resuspended in 1X binding buffer at a 
concentration of one million cells per one milliliter.  To one hundred thousand cells 5μl of PI and 5μl of Annexin V-
FITC were added, and cells were incubated at room temperature for 15 minutes.  At the end of incubation period, 
400μl of 1X binding buffer were added to the staining reaction and cells were analyzed immediately using a Becton 
Dickinson FACSVantage DiVa.  Appropriate compensation tubes were used to set up the instrument – unstained 
cells, cells stained with PI only (no Annexin V-FITC), and cells stained with Annexin V-FITC only (no PI).  Dot 
plots representing PI fluorescence against Annexin V-FITC fluorescence were analyzed using BD FACSDiva 
software 6.1.1.  
2.9 SISTER CHROMATID EXCHANGES 
Human ES cells were harvested using accutase and pelleted as described earlier 2.5.  Medium was aspirated and one 
milliliter of prewarmed 0.75 mM KCl (Sigma) added drop wise while gently tapping the tube.  Additional four 
milliliters of prewarmed hypotonic KCl solution was added and cells were allowed to swell in water bath at 37oC for 
20 – 30 minutes.  Ten drops of cold fixative (one part of acetic acid and three parts of methanol; all Sigma) were 
used as prefix, and cells were incubated for five minutes at room temperature.  Following centrifugation, supernatant 
was discarded and fresh cold fixative added for 30 minutes.  This step was repeated two more times, for total of 
three fixation steps.  Following last fixation step, cells were dropped onto slides and left to dry and age for at least 
one day before staining. 
 Aged slides were rehydrated in PBS and stained in 50 μg/ml Hoechst 33258 (Invitrogen) in dark for 15 
minutes.  Following a wash in PBS, slides were placed in 2X SSC (0.3 M sodium chloride and 30 mM tri-sodium 
citrate dihydrate, pH 7.0; Invitrogen) on a 55oC hotplate and exposed to UV at a distance less than 10cm for 15 
minutes.  Slides were rinsed in PBS and stained in 4% Giemsa for 10 – 15 minutes.  Metaphase spreads were 
visualized using light microscopy and number of chromosomes and sister chromatid exchanges (SCE) counted.  
Twenty-five metaphase spreads were analyzed per condition.  Results are presented as a number of SCE per 
chromosome per cell. 
2.10 STATISTICAL ANALYSIS 
Means and SEMs were calculated, and statistical significance for categorical data was determined by χ2 test. The 
significance was determined at p<0.05. P–values for SA Biosciences PCR arrays were calculated using web-based 
analysis software available at http://sabiosciences.com/pcrarraydataanalysis.php. Each cell line was run at least three 
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times. The p-values were calculated based on two-tail Student’s t-test with equal variance and statistical significance 
was determined at p<0.05. 
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3.0  HUMAN EMBRYONIC STEM CELLS EXHIBIT ATM DEPENDENT G2/M CELL CYCLE 
ARREST 
This chapter was published as a research article in Stem Cells: 
Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not 
G(1) cell cycle arrest in pluripotent human embryonic stem cells. Olga Mom ilovi , Serah Choi, Sandra Varum, 
Christopher Bakkenist, Gerald Schatten, Christopher Navara. 2009 Aug;27(8):1822-35. 
3.1 ABSTRACT 
Human embryonic stem (ES) cells are highly sensitive to environmental insults including DNA damaging agents, 
responding with high levels of apoptosis.  In order to understand the response of human ES cells to DNA damage, 
we investigated the function of the ataxia telangiectasia mutated (ATM) DNA damage signaling pathway in 
response to γ-irradiation.  Here we demonstrate for the first time in human ES cells that ATM kinase is 
phosphorylated and properly localized to the sites of DNA double strand breaks within 15 minutes of irradiation.  
Activation of ATM kinase resulted in phosphorylation of its downstream targets:  CHEK2, TP53 and NBS1.  In 
contrast to murine ES cells, CHEK2 and TTP53 were localized to the nucleus of irradiated human ES cells.  We 
further show that irradiation resulted in a temporary arrest of the cell cycle at the G2, but not G1 phase.  Human ES 
cells resumed cycling approximately 16 hours post irradiation, but had a four fold higher incidence of aberrant 
mitotic figures compared to non-irradiated cells.  Finally, we demonstrate an essential role of ATM in establishing 
G2/M arrest, since inhibition with the ATM specific inhibitor KU55933 resulted in abolishment of G2/M arrest, 
evidenced by an increase in the number of cycling cells two hours after irradiation.  In summary, these results 
indicate that human ES cells activate the DNA damage checkpoint, resulting in an ATM dependent G2/M arrest.  




Since all organisms are continually exposed to environmental and metabolic factors that cause DNA damage, 
eukaryotic cells have developed elaborate cell cycle checkpoint control and DNA repair mechanisms that act in an 
orchestrated manner to arrest the cell cycle until the damage is repaired (Jackson, 2002; Khanna and Jackson, 2001). 
Failure to do so can have detrimental consequences – transmission of genetic defects to the daughter cell or cell 
death.  If DNA damage cannot be repaired, cells containing DNA damage may undergo apoptosis, removing their 
damaged DNA from the pool of cycling cells (Jackson, 2001; Jackson, 2002; Norbury and Hickson, 2001; Rich et 
al., 2000).  
Ionizing radiation induces a variety of DNA lesions in exposed cells (Goodhead, 1989; Hutchinson, 1985; 
Ward, 1988), of which DNA double strand breaks (DSB) are particularly toxic because they are more difficult to 
repair due to the loss of integrity of both DNA strands (Karagiannis and El-Osta, 2004).  In somatic cells, ionizing 
radiation induced DNA damage signaling is initiated by the DSB sensor ataxia telangiextasia mutated (ATM) kinase 
(Lavin et al., 2005).  ATM is a member of the phosphatydilinositol 3’-kinase (PI3K)-related kinase family, but it 
phosphorylates protein rather than lipid substrates.  In the presence of DSB ATM becomes activated and 
phosphorylates numerous downstream targets, including CHEK2 and TTP53, which act as signal transducers and 
effectors that initiate cell cycle arrest and apoptosis in G1, S and G2 phases of the cell cycle (Niida and Nakanishi, 
2006). 
While DNA damage responses have been extensively studied in somatic cells in vitro, the limiting nature of 
the available tissues and the ethical concerns in studying early human development in vivo  have precluded  
studying DNA damage responses during very early human development.  The successful isolation of human ES cells 
from blastocyst embryos by Thomson et al. (Thomson et al., 1998) enables these pluripotent, immortal cells to be 
used to study the corresponding developmental stages in vitro.   
It has been reported that both mouse and non-human primate ES cells have developed modifications of 
checkpoint response that allow them to escape G1/S arrest and to arrest in G2/M instead (Aladjem et al., 1998; 
Fluckiger et al., 2006; Hong and Stambrook, 2004).  In mouse ES cells two main pathways that become activated 
after DNA damage and lead to G1/S checkpoint activation in somatic cells, namely ATM-CHEK2-CDC25A and 
ATM-TTP53-CDKN1A, are compromised (Hong and Stambrook, 2004).  Mouse ES cells mis-localize and fail to 
activate CHEK2, do not express CDKN1A, and respond to DNA damage with high levels of apoptosis (Aladjem et 
al. 1998; Hong and Stambrook 2004; Chuykin et al. 2008).  In addition, conflicting reports of TP53 localization and 
activity have been described in mouse ES cells in response to DNA damage.  It has been demonstrated that mouse 
ES cells do not activate TP53-dependent DNA damage responses, undergo TP53-independent apoptosis in response 
to ionizing radiation, and do not translocate TP53 to the nucleus after DNA damage (Aladjem et al., 1998; Hong and 
Stambrook, 2004).  Other report however, has stated that after irradiation TP53 induces differentiation of mouse ES 
cells by suppressing NANOG expression through direct binding to the NANOG promoter (Lin et al., 2005), implying 
that TP53 is successfully translocated to the nucleus. 
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In this study we examined the events in the ATM kinase dependent checkpoint signaling pathway and cell 
cycle arrest in human ES cells following exposure to two grays of γ-radiation.  We demonstrated phosphorylation 
and localization of ATM at the sites of DNA DSB, as well as phosphorylation and nuclear localization of ATM 
downstream targets, CHEK2 and TP53, similar to that in irradiated human somatic cells.  We further showed that 
irradiated human ES cells arrest in G2/M, but not in the G1/S phase of the cell cycle.  We used the ATM-specific 
inhibitor KU55933 to evaluate the role of ATM in effecting this G2/M arrest.  Checkpoint signaling in irradiated 
human ES cells was inhibited using KU55933, but only at concentrations ten fold higher than that necessary to 
inhibit ATM function in somatic cells.  Inhibition of ATM function compromised G2/M arrest in human ES cells, 
and irradiated cells proceeded to mitosis in the presence of KU55933. 
3.3 RESULTS 
3.3.1 Pluripotency and radiosensitivity in human embryonic stem cells 
Both mouse and human ES cells have been reported to reduce the expression of NANOG and differentiate in 
response to DNA damage (Lin et al., 2005; Qin et al., 2007).  In order to confirm the populations of cells that we 
were studying were pluripotent human ES cells, we followed the expression of the pluripotency transcription factors 
NANOG and POU5F1 by quantitative PCR (Figure 1A), Western blot (Figure 1B, 1C) and immunocytochemistry 
(Figure 1D, E) for 24 hours following two grays irradiation. Additionally, we examined the cell surface markers 
CD9 (Figure 1A), and SSEA4 (Figure 1F).  We observed that the mRNA levels for CD9, NANOG and POU5F1 
decreased relative to non-irradiated cells six hours following irradiation, similar to what has been described in 
mouse and human ES cells previously (Lin et al., 2005; Qin et al., 2007) (Figure 1A).  However, when we continued 
to follow human ES cells at later time points, the mRNA levels returned to those values observed in non-irradiated 
cells by 24 hours post irradiation.  We did not detect a similar decrease in the protein level of NANOG and OCT4 
(Figure 1B).  In accordance with the Western blot results, OCT4 (Figure 1C), NANOG (Figure 1D), and SSEA4 
(Figure 1E) were detected in human ES cells prior to and following irradiation by immunocytochemistry.  
Additionally, we exposed human ES cells to one gray of ionizing radiation, and left them to recover for one, two, 
four and six days post irradiation.  At the given time points we collected floating cells and adherent cells separately, 
and analyzed expression of NANOG and OCT4 by Western blot (Figure 1C).  We discovered there was no change 
in the expression of NANOG and OCT4 in the adherent cells during one week recovery following one gray of 
radiation.  However, in the population of floating cells, the expression of NANOG and OCT4 was completely lost. 
Furthermore, when we irradiated human ES cells with one Gy, left them to recover for six days, and inject them into 
immunocompromised mice, teratomas composed of three germ layers were formed (Figure 2). 
Following exposure to five grays of ionizing radiation, large holes began appearing in the colonies within 
six hours (Figure 1D, Figure 3A, right).  To determine if this was cell death, as previously reported for ES cells 
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(Aladjem et al., 1998; Hong and Stambrook, 2004; Qin et al., 2007), or a detachment of cells from the substrate, we 
performed a Western blot for cleaved caspase-3 (Figure 3B) and flow cytometry for Annexin V and propidium 
iodide (PI; Figure 3C) following exposure to two grays of γ-radiation.  Cleaved caspase-3 began appearing in the 
samples four hours after irradiation and continued to increase for at least 24 hours.  A marked increase in percentage 
of cells positive for Annexin V and doubly positive for propidium iodide was observed eight hours following 
irradiation.  This finding confirms that the observed loss of cells was due to cell death, most likely via apoptosis.  
We also noted a change in size of the cells.  We believe this is not due to differentiation, as demonstrated by 




Figure 1:  Pluripotency of irradiated human embryonic stem cells.  
(A): Human ES cells were irradiated, or left untreated, and allowed to recover for the indicated time periods prior to 
collection.  Total RNA was isolated and the expression of pluripotency markers CD9, NANOG and POU5F1 
analyzed by TaqMan human stem cell pluripotency array.  The mRNA fold changes were calculated using the -
ΔΔCt method and normalized using ACTB as endogenous control.  The results in non-irradiated cells were 
normalized to one, and the value in irradiated cells was calculated in respect to this.  (B): Western blot analysis of 
NANOG and OCT4 protein levels following the irradiation of human ES cells.  (C): Protein level of NANOG and 
OCT4 in human ES cells that were irradiated with one gray of γ-irradiation and left to recover for the indicated 
periods of time.  Whole cell lysates of adherent and floating cells were collected separately and analyzed by Western 
blot.  α-tubulin served as the loading control.   Confocal microscopy for (D): OCT4, (E): NANOG, and (F): SSEA4 
in human ES cells at indicated time points after irradiation.  Bar = 100μm (D), 50μm (E, F). 
 
Figure 2:  Pluripoterncy of irradiated human embryonic stem (ES) cells. 
One week after irradiation with one Gy human ES cells were injected into mice and three months later teratomas comprised of 
ectoderm (A, D), mesoderm (B, E), and endoderm (C, F) developed.  (A): developing skin with sensory patches, (B) developing 
cartilage, (C) developing gastro-intestinal tissue, with examples of cartilage, (D): developing neuronal rossetes with surrounding 
blood vessels. (E): maturing cartilage with surrounding periosteum, (F): maturing gastro-intestinal epithelium. 
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Figure 3:  Radiosensitivity of human embryonic stem cells.  
(A): Phase contrast imaging of irradiated and non-irradiated human ES cells at the indicated time points. (B): 
Western blot analysis for cleaved caspase-3 following irradiation. α-tubulin served as the loading control.  (C):  
Flow cytometry for Annexin V-FITC and PI of non-irradiated cells and eight hours post irradiation of human ES 
cells. 
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3.3.2 ATM activation in human embryonic stem cells 
ATM kinase activation is one of the earliest and most sensitive responses to DNA damage in irradiated cells 
(Abraham, 2001).  Following γ-irradiation ATM is recruited to the sites of DSB, where it becomes activated through 
autophosphorylation at serine 1981 (Bakkenist and Kastan, 2003).  We investigated ATM phosphorylation at this 
residue by Western blot (Figure 4A).  Phosphorylation of ATM at serine 1981 was detected in human ES cells one 
hour following exposure to two grays of γ-radiation.  High levels of this phosphorylation were maintained until four 
hours following irradiation, at which point the levels declined, but remained above steady state for at least 24 hours.  
During the same time frame, the level of total ATM protein did not change.  Localization of ATM to the sites of 
DNA DSB was investigated by co-localization with the DNA DSB marker, γ-H2AX (Figure 4B).   
Figure 4:  ATM autophosphorylation and localization in human embryonic stem cells.   
(A): Western blot of ATM-serine 1981 and total ATM at the indicated time points following γ-irradiation.  α-tubulin 
served as the loading control.  (B): ATM-serine 1981 localizes to the sites of DNA DSB after irradiation, 
demonstrated by co-localization with a marker of DSB, γ-H2AX.  Blue – DNA, Green – ATM-serine 1981, Red – γ-
H2AX, Yellow – Co-localization.  Bar = 10μm. 
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Phosphorylated ATM was detected only weakly in non-irradiated cells, but ATM-serine 1981 co-localized 
with γ-H2AX foci 15 minutes after irradiation.  The number of γ-H2AX foci increased immediately following 
irradiation and returned close to basal levels within 24 hours.  Furthermore, we double labeled cells for ATM-serine 
1981 and NANOG and analyzed them by confocal microscopy (Figure 5), confirming that the ATM response occurs 
in pluripotent (NANOG-positive) human ES cells.  Human ES cells are known to cycle rapidly through the growth 
phases following passaging and to decrease proliferation as they approach the next passage.  We performed 
immunocytochemistry for ATM-Ser1981 and NANOG on day four and day seven following passaging to ensure 
that the kinetics of ATM signaling was not dependent on the cells’ growth phase.  The kinetics of ATM activation 
was identical in both cases, as is observed in Figure 5.  
Figure 5:  ATM activation in pluripotent human embryonic stem cells.   
Double labeling of human ES cells with NANOG and ATM-serine 1981.  Blue – DNA, Green – NANOG, Red – 
ATM-serine 1981. Bar = 10μm. 
3.3.3 Activation of ATM downstream targets in human embryonic stem cells 
Activated ATM phosphorylates numerous substrates at the sites of DSB, activating downstream signal transducers 
(Banin et al., 1998; Canman et al., 1998; Matsuoka et al., 2000; Melchionna et al., 2000).  Phosphorylation of 
CHEK2 and TP53 is essential for induction of checkpoint arrest, whereas phosphorylation of NBS1 facilitates 
formation of MRE11/RAD50/NBS1 foci that are implicated in DNA repair (Carney et al. 1998).  We monitored the 
phosphorylation of these ATM targets by Western blot analysis using phospho-specific antibodies (Figure 6).  
Phosphorylation of CHEK2 at threonine 68 (Figure 6A) was maximal one hour following irradiation and rapidly 
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declined thereafter, so that only a small fraction was still phosphorylated at six hours.  The level of total CHEK2 did 
not change over the same time course.  NBS1 phosphorylation at serine 343 (Figure 6A) followed a similar time 
course, peaking one hour after irradiation and returning to control levels by 24 hours.  Again, there was no change in 
total protein level during this time frame. 
 
Figure 6:  Phosphorylation and localization of CHEK2 and TP53 in human embryonic stem cells.   
(A): Western blot of CHEK2-threonine 68, total CHEK2, NBS1-serine 343, and total NBS1.  (B): Time-course 
immunocytochemistry of CHEK2-threonine 68 following irradiation of human ES cells.  (C): Confocal microscopy 
of CHEK2-threonine 68 revealing its centrosomal location (arrowheads) in non-irradiated human ES cells. Blue – 
DNA, Green – CHEK2-threonine 68, Red – β-tubulin.  Bar = 10μm.  (C): Western blot of TP53-serine 15, TP53-
serine 20, and total TP53.  (D): Confocal microscopy of TP53-serine 15 following radiation treatment.  α-tubulin 
served as the loading control for Western blots.  Blue – DNA, Green – TP53-serine 15.  Bar = 10μm.   
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Canonically, CHEK2 is activated at DNA DSB by a mechanism that requires ATM kinase dependent 
phosphorylation on threonine 68 (Matsuoka et al., 2000), and localizes diffusely throughout the nucleus of the 
irradiated somatic cells (Lukas et al., 2003).  In contrast to observations in somatic cells, phosphorylated CHEK2 
has been described to localize to the centrosomes of mouse ES cells (Hong and Stambrook, 2004).  We have also 
observed localization of CHEK2-threonine 68 to the mitotic spindle poles in non-irradiated human ES cells (Figure 
6B).  However, phosphorylated CHEK2 was detected in the nucleus 20 minutes after  irradiation of human ES cells 
(Figure 6C), unlike published reports in mouse ES cells (Hong and Stambrook, 2004).  Levels detected by 
immunocytochemistry followed a similar time course to those observed by Western blot analysis, with nuclear 
levels decreasing rapidly after two hours. 
Both ATM and CHEK2 kinases phosphorylate and thereby stabilize and activate TP53.  ATM 
phosphorylates TP53 at serine 15 (Banin et al. 1998; Canman et al. 1998), whereas CHEK2 phosphorylates TP53 at 
serine 20 in response to activation by ATM (Hirao et al. 2000; Shieh et al. 2000).  We examined phosphorylation of 
these serine residues following irradiation using Western blot analysis (Figure 6D).  Non-irradiated human ES cells 
had no detectable TP53 phosphorylated at serine 15 or serine 20, but within one hour of irradiation, phosphorylation 
of serine 15 and serine 20 was detected, reached maximal levels by two hours, declined thereafter, remaining 
elevated above baseline for 24 hours.  The level of total TP53 also increased after irradiation (Figure 6D) most likely 
due to TP53 stabilization following its phosphorylation (Chehab et al., 1999; Tibbetts et al., 1999).  We also 
analyzed the phosphorylation of CHEK2 and TP53 in detached, presumably dying, human ES cells six and 24 hours 
after irradiation (Figure 6E).  We observed the response in detached cells is in accordance with the response of 
adherent cells at these time points post irradiation. 
Conflicting results regarding TP53 subcellular localization have been reported in mouse and human ES 
cells (Aladjem et al. 1998; Hong and Stambrook 2004; Lin et al. 2005; Qin et al. 2007; Chuykin et al. 2008).  Our 
data show that TP53-serine 15, detected using two different TP53-serine 15 antibodies, is nuclear in two human ES 
cell lines (WA07, and WA09 not shown) following irradiation, by both immunocytochemistry (Figure 6F) and 
immunohistochemistry (Figure 7).  Our results demonstrate that non-irradiated human ES cells have no detectable 
nuclear staining for phospho-TP53.  Twenty minutes after irradiation, both the number of TP53-positive nuclei and 
the intensity of staining increased, peaked at two hours, and declined thereafter, similar to Western blot results 
(Figure 6D).  Localization of TP53 to the nucleus followed a dose dependency, as higher levels of radiation induced 
a stronger response when examined at the same time point (three hours;  Figure 8).  Human ES cells were irradiated 
with 0, 2, 5, 7, 9, and 30 grays, and fixed three hours post irradiation.  Immunohistochemistry demonstrates very 
faint nuclear staining for TP53-serine 15 in non-irradiated cells.  Following increasing doses of irradiation the 
number of TP53-serine 15 positive nuclei and the intensity of staining increase at this time point.  In addition, cell 




Figure 7:  Localization of TP53-serine 15 to the nuclei of irradiated human embryonic stem (ES) cells.  
Immunohistochemistry for TP53-serine 15.  Note that six hours post irradiation holes in the colony appear, 
supporting the earlier observation of human ES cell sensitivity to irradiation.  Bar = 100μm. 
 
  Figure 8:  Dose-dependent TP53-serine 15 response in human ES cells.   
3.3.4 Cell cycle arrest following irradiation in human embryonic stem cells 
We next investigated whether human ES cells halt progression through the cell cycle in response to γ-irradiation.  
We compared the proliferation of the human ES cells on day five and day seven after passaging, and observed that 
the cells remain actively proliferating on the later day of the cell culture (Figure 9).  Therefore, for the following 
studies we used cells on the later day of the cell culture. 
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Figure 9:  Human embryonic stem cell proliferation.   
Human ES cells are actively proliferating on day five and day seven after passaging.  Human ES cells were labeled 
with EdU 30 minutes prior to harvesting on day five (left) and day seven (right) after passaging.  Cells were 
collected, stained for EdU and PI, and analyzed by flow cytometry.  Dot plots (top) represent EdU fluorescence 
versus DNA content determined with PI.  Following gating, the G1, S, and G2/M phase cells were depicted on the 
DNA histograms (bottom).  The table represents the percentage of cells in each stage of the cell cycle on day five 
and day seven after passaging.   
 
In order to assess the cell cycle profile of irradiated human ES cells, we performed flow cytometric analysis 
of DNA content using PI (Figure 10A).  Similar to non-human primate (Fluckiger et al., 2006) and mouse (Hong 
and Stambrook, 2004) ES cells, irradiated human ES cells arrested in G2/M phase of the cell cycle.  The percentage 
of cells in G1 was significantly reduced four hours following irradiation, and essentially no cells were detected in G1 
eight hours after irradiation.  Human ES cells returned to the cell cycle 16 hours post irradiation indicated by a 
decrease in the percentage of cells in G2/M between 16 and 20 hours (Figure 10A).  By 48 hours the cell cycle 
distribution closely resembled non-irradiated cells.   
In order to further understand the events that occurred following release from cell cycle arrest, we 
performed immunostaining with the mitosis-specific marker histone H3-serine 10 (Figure 10B).   Twenty minutes 
after irradiation, cells continued to divide and these mitotic figures were indistinguishable from controls (Figure 
10B).  Two hours following irradiation, no histone H3-serine 10 positive cells were detected, suggesting that cells 
were arrested in G2 phase.  Similarly, six hours following irradiation, no dividing cells were observed and there was 
a considerable amount of cell death.  Mitotic figures began to be detected 20 hours after irradiation, indicating that 
cells returned to the cell cycle.  We determined the mitotic indexes prior to, and 24 hours post irradiation (Figure 
10C, right).  There was no significant difference in quantified mitotic index between non-irradiated (3.91±0.50%) 
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and irradiated (3.57±0.37%, 0.5<p<0.7, n=3) cells, but a high percentage of cells entering mitosis 24 hours after 
irradiation displayed aberrant mitotic spindles (Figure 10D, Materials and Methods).  The presence of aberrant 
mitotic figures, including anaphase bridges, multipolar spindles, lagging and misaligned chromosomes, was elevated 
to 414.51±45.98%, in comparison to non-irradiated cells (100±38.86%, p<0.001, n=3; Figure 10C, left).   
Figure 10:  Cell cycle analysis of irradiated human embryonic stem cells.   
(A): Analysis of DNA content of human ES cells after irradiation by flow cytometry using PI; left panel: cell cycle 
profiles, as measured 0-48 hours after irradiation of human ES cells; right panel: percentages of cells in G1, S and 
G2/M as a function of time following irradiation.  Percentages were calculated using ModFit software (Verity 
Software house, Topsham, ME).  Results were gated to exclude cellular debris, sub G0 population, and doublets.  
Data presented are means ± SEM calculated from three independent experiments.  The table represents the 
percentage of cells in each stage of the cell cycle after irradiation.  (B): Histone H3-serine10 time course 
immunocytochemistry in irradiated human ES cells.  (C): Left panel: Quantification of mitotic indexes in non-
irradiated cells and 24 hours post irradiation.  Human ES cells were irradiated, or left untreated and fixed 24 hours 
later.  Coverslips were stained with histone H3-serine10 antibody and the percentage of histone H3-serine10 positive 
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(mitotic) cells was determined.  The data represent mean ± SEM from three independent experiments.  At least 1000 
cells were analyzed per condition in each experiment.  Statistical significance was determined by Chi-Square test.  
n.s. – not significant.  Right panel: Quantification of percentage of aberrant mitotic figures in non-irradiated and 
irradiated human ES cells.  Cells were treated as in left panel, and assayed for the presence of aberrant mitotic 
figures.  Three independent experiments were performed, and at least 100 mitotic figures were analyzed per 
condition in each experiment.  The result in non-irradiated cells was normalized to 100%, and the value in irradiated 
cells was calculated in respect to this.  Statistical significance was determined by Chi-Square test.  *** p<0.001.  
(D): Examples of normal (top row) and aberrant (bottom row) mitotic figures visualized by confocal microscopy.  P 
– prophase, PM – prometaphase, M – metaphase, A – anaphase, T – telophase, B – anaphase bridge, asterisk – poles 
of mitotic spindle, arrowheads – misaligned chromosomes.  Blue – DNA, green – histone H3-serine 10, red – β-
tubulin.  Bar = 10μm. 
 
We assayed the expression of G1/S cell cycle regulators – retinoblastoma (RB) tumor suppressor and 
CDKN1A (Figure 11).  Retinoblastoma protein is a negative regulator of G1 to S cell cycle transition, and has been 
reported to be in its inactive, hyperphosphorylated, form in the mouse ES cells (Savatier et al., 1994).  CDKN1A is 
essential negative regulator of the cyclin dependent kinase 2 (CDK2) that is under TP53 transcriptional control, and 
whose expression is stimulated following DNA damage.  Mouse ES cells have been shown to lack induction of 
Cdkn1A that explains the absence of the G1/S cell cycle arrest in these cells (Hong and Stambrook, 2004).  We 
determined the level of RB protein phosphorylated at several serine residues – serine 790, serine 795, and serine 
807/811.  We found that RB is phosphorylated at these residues at all investigated time points following irradiation, 
suggesting that it remains in its inactive and cell cycle permissive form (Figure 11).  The induction of CDKN1A 
protein level was very weak, suggesting that it may be insufficient to maintain G1/S arrest (Figure 11B). 
 
Figure 11:  Protein level of G1 cell cycle regulators in human embryonic stem cells. 
(A):  Western blot of RB-serine 790, RB-serine 795, and RB-serine 807/811.  (B): Western blot of CDKN1A.  α-
tubulin served as the loading control for Western blots.   
 
The appearance of mitotic cells 16-20 hours after irradiation can be explained 1) by arrested cells 
reentering the cell cycle, or 2) by cells that were in the very early stages of G1 reaching mitosis 16-20 hours after 
irradiation and never arresting.  We performed a pulse chase experiment in which we labeled human ES cells with a 
thymidine analogue, 5-ethynyl-2’-deoxyuridine (EdU) for 30 minutes just prior to irradiation in order to distinguish 
between these two possibilities.  EdU was washed out following the 30 minute pulse, cells were collected at 4, 8, 16 
and 24 hours post irradiation, and analyzed by flow cytometry (Figure 12).  The pulse only labeled the human ES 
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cells in S phase at the time of irradiation.  Eight hours after irradiation, these cells have clearly moved into the G2/M 
phase of the cell cycle.  At 16 hours, the first G1 cells which stain for EdU are observed, indicating that arrested cells 
have undergone mitosis.  Additionally, in the dot plot it is observed that the G1 population has a lower EdU signal, 
as would be expected after mitosis.   
Figure 12:  Human embryonic stem cells resume the cell cycle following irradiation induced G2/M arrest. 
Human ES cells were pulse labeled with EdU prior to irradiation, exposed to two grays of γ-radiation, and left to 
recover for 4, 8, 16, and 24 hours, without addition of EdU.  At indicated time points following irradiation, human 
ES cells were collected, stained for EdU and propidium iodide, and analyzed by flow cytometry.  Dot plots (left) 
represent EdU fluorescence versus DNA content determined with PI.  Following gating, the EdU-positive cells 
(blue) were plotted together with the single cells (green) on DNA histograms (on the right).  Note that EdU-positive 
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cells are cells that were in the S phase at the time of irradiation, and do not necessarily represent S-phase cells at any 
of the time points following irradiation.   
3.3.5 ATM is required for the G2/M arrest in human embryonic stem cells 
In order to test if ATM signaling is necessary for G2/M arrest, we inhibited ATM kinase using the ATM-specific 
inhibitor KU55933 (Hickson et al. 2004).  To the best of our knowledge, KU55933 inhibits ATM kinase activity in 
all somatic cells examined to date, when added to the cell culture medium at a concentration of 10 μM (Hickson et 
al., 2004; White et al., 2008).  However, our titration experiments revealed that this dose is only partially effective in 
human ES cells, and that 100 μM is needed to inhibit ATM signaling (Figure 13A).  ATM phosphorylation and 
activity are maximal one hour after irradiation, thus, we titrated the concentration of KU55933 needed to inhibit the 
ATM function in human ES cells at this time point.  We treated cells starting one hour prior to irradiation (minus 
one hour) until one hour post irradiation (plus one hour) with vehicle (DMSO), 10 μM, 50 μM and 100 μM 
KU55933.  A dose-dependent decrease in the level of ATM-serine 1981, CHEK2-threonine 68, TP53-serine 15, and 
NBS1-serine 343 following the addition of increasing concentration of KU55933 confirmed inhibition of ATM 
signaling in irradiated human ES cells.  Under the same treatment, the level of total ATM, CHEK2 and NBS1 did 
not change.  Similarly, treatment with KU55933 dramatically reduced TP53 stabilization after irradiation.   
In order to determine if ATM activation is necessary for G2/M arrest, we performed histone H3-serine 10 
immunocytochemistry and determined mitotic index two hours after irradiation in cells in which ATM kinase was 
inhibited.  Human ES cells were treated starting one hour prior to irradiation (minus one hour) until two hours post 
irradiation (plus two hours) with vehicle (DMSO) or 100 μM KU55933, fixed and stained with histone H3-serine 10 
antibody (Figure 13B).  No significant difference in mitotic index was observed between non-irradiated cells treated 
with DMSO (2.85±0.53%) and KU55933 (2.60±0.21%, 0.3<p<0.5, n=3; Figure 13C).  However, two hours after 
irradiation, KU55933 treated cells had higher mitotic index (1.35±0.34%) than DMSO treated cells (0.16±0.02%, 
p<0.001; Figure 13C), suggesting that ATM function is required for functional G2/M arrest in human ES cells.  
However, even this high dose (100 μM) of ATM inhibitor did not completely restore the mitotic index in irradiated 
cells (1.35±0.34%) to the one detected in non-irradiated cells (2.60±0.21%).  
Finally, we characterized mitotic cells that were observed following irradiation of KU55933 treated cells.  
The percentage of aberrant mitotic figures following irradiation of KU55933 treated cells was elevated 
(229.01±36.15%, p<0.001, n=3; Figure 13D) compared to KU55933 treated non-irradiated cells (100±4.56%).  The 
most prevalent type of mitotic error was anaphase bridges.  We did not observe a statistically significant difference 
in the frequency of aberrant mitotic figures between vehicle (78.03±22.44%) and KU55933 (100±4.56%, p>0.1, 
n=3) treated non-irradiated cells. 
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Figure 13:  Inhibition of ATM signaling with KU55933 in human embryonic stem cells.   
(A): Western blot for ATM-serine 1981, ATM, CHEK2-threonine 68, CHEK2, TP53-serine 15, TP53, NBS1-serine 
343, and NBS1 in human ES cells.  Human ES cells were pretreated with vehicle (DMSO) or 10 μM, 50 μM, and 
100 μM KU55933 for one hour (minus one hour), irradiated, or left untreated, and harvested one hour later (plus one 
hour).  α-tubulin served as the loading control.  (B):  Human ES cells were treated with vehicle (DMSO) or 100 μM 
KU55933 starting one hour before irradiation (minus one hour), irradiated, or left untreated, and fixed two hours 
later (plus two hours), stained for histone H3-serine10 and analyzed by confocal microscopy.  (C): Quantification of 
mitotic indexes of KU55933 or vehicle treated non-irradiated and irradiated cells.  Human ES cells were treated as 
in (B), and the percentage of mitotic cells was quantified two hours post irradiation.  Three independent experiments 
were performed, and at least 1500 cells were analyzed per condition in each experiment.  The data represents means 
± SEM.  Statistical significance was determined by Chi-Square test.  n.s. – not significant; *** p<0.001.  (D): 
Quantification of percentage of aberrant mitotic figures in KU55933 treated cells.  Human ES cells were treated as 
in (A), and assayed for the presence of aberrant mitotic figures.  The percentage of aberrant mitotic figures in non-
irradiated KU55933 treated cells was normalized to 100%, and the value in irradiated KU55933 treated cells was 
calculated in respect to this.  Three independent experiments were performed, and at least 100 mitotic figures were 
analyzed per condition in each experiment.  Statistical significance was determined by Chi-Square test.  *** 




Several phenotypes associated with response of embryonic stem cells to DNA damage are: 1) they reduce 
expression of pluripotency factors (Lin et al., 2005; Qin et al., 2007), 2) they lack a G1/S checkpoint (Fluckiger et 
al., 2006; Hong and Stambrook, 2004), and 3) they are extremely sensitive to DNA damaging agents resulting in cell 
death within several hours of exposure to DNA damaging agents (Aladjem et al., 1998; Hong and Stambrook, 2004; 
Qin et al., 2007).  Additionally, a number of cell cycle regulatory proteins have been demonstrated to have aberrant 
functions in ES cells with sometimes conflicting results reported between laboratories.  In this study, we sought to 
investigate the functioning of the ATM signaling cascade in human ES cells, including analysis of the cell cycle 
distribution after ionizing radiation.  We found that ATM signaling is intact and that human ES cells activate and 
properly localize the checkpoint signaling proteins ATM, CHEK2 and TP53, resulting in a temporary G2/M arrest 
before the cells resume mitosis.  Furthermore, our results describe an essential role of ATM in induction of G2/M 
arrest, as an ATM specific inhibitor, KU55933, inhibits this G2/M arrest.   
Firstly, we investigated the expression of pluripotency markers NANOG, OCT4, CD9, and SSEA4 after 
irradiation.  Surprisingly, we found that the protein levels do not change over the 24 hour period following 
irradiation, suggesting that human ES cells remained pluripotent.  This observation is in contradiction with reports 
of DNA damage induced differentiation of mouse (Lin et al., 2005) and human (Qin et al., 2007) ES cells.  
However, in these studies authors investigated the mRNA levels within six hours of irradiation.  When we examined 
mRNA levels, we also observed a drop at six hours following irradiation.  However, at 24 hours the levels returned 
to near that of controls.   
Embryonic stem cells of different species show tremendous sensitivity to DNA damage and undergo 
extensive cell death within hours of DNA damage.  In this paper, we demonstrated cell death within hours following 
exposure of human ES cells to two grays of γ-irradiation.  Cleavage of caspase-3 was detected four hours after 
irradiation, and cell loss was visualized six hours post irradiation.  Interestingly, human embryonal carcinoma (EC) 
cells display a higher survival rate following ionizing radiation, when compared to their differentiated counterparts 
(Wang et al., 2009).  After confirming the radiosensitivity of human ES cells, we investigated checkpoint signaling 
and function in irradiated human ES cells.  
 ATM is rapidly activated in cells exposed to agents that induce DNA double strand breaks (Abraham, 
2001).  Cells deficient in ATM exhibit hypersensitivity to radiation and radiomimetic drugs, defective cell cycle 
arrest, increased chromosome breakage, and reduced TP53 response following irradiation (Rudolph and Latt, 1989; 
Taylor et al., 1979; Xu and Baltimore, 1996; Young and Painter, 1989).  Cell cycle checkpoint defects include a 
diminished arrest in G1, radioresistant DNA synthesis, and reduced arrest in G2 (Rudolph and Latt, 1989; Xu and 
Baltimore, 1996; Young and Painter, 1989).  In this study, we monitored the kinetics of ATM phosphorylation and 
localization to the sites of DNA DSB.  Confocal microscopy revealed that ATM was phosphorylated and recruited 
to the DNA DSB in human ES cells within 15 minutes of irradiation.  Phosphorylation of ATM and its target 
proteins CHEK2, TP53, and NBS1 reached maximum within the first hour of irradiation, suggesting activation of 
checkpoint signaling in human ES cells. 
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Hong and Stambrook (Hong and Stambrook, 2004) reported that CHEK2 is hyperphosphorylated and 
localized to the centrosomes in mouse ES cells rather than diffusely distributed in the nucleus, making it unavailable 
to act as a motile signal transducer.  We also observed phosphorylated CHEK2 at the poles of mitotic spindle in non-
irradiated human ES cells (Figure 6).  However, in contrast to mouse ES cells, phospho-CHEK2 was mobilized to 
the nucleus of human ES cells within 20 minutes of irradiation.  Centrosomal CHEK2 was detected in non-irradiated 
somatic cells as well, and mobilized to the nucleus in response to DNA damage (Zhang et al., 2007), in agreement 
with its canonical role as a mobile signal transducer.  In addition, several proteins involved in DNA damage 
response, such as ATM (Oricchio et al., 2006; Zhang et al., 2007), ATR (Zhang et al., 2007), ATRIP (Zhang et al., 
2007), CHEK1 (Kramer et al., 2004), TP53 (Ciciarello et al., 2001), and BRCA1 (Hsu and White, 1998) have been 
detected to associate with centrosomes during mitosis.  Based on these emerging data, it has been suggested that 
centrosomes might have a functional role in DNA damage responses, serving either as “command centers” (Doxsey, 
2001), where DNA damage response proteins come in close proximity and/or are sequestered from unfavorable 
interactions, or as a subject of DNA damage response (Loffler et al., 2006). 
Conflicting results regarding TP53 localization have been reported in ES cells.  Several groups have 
reported that TP53 is not translocated into the nucleus of mouse ES cells after DNA damage (Aladjem et al., 1998; 
Chuykin et al., 2008; Hong and Stambrook, 2004).  In contrast, other data suggest that TP53 induces differentiation 
in mouse (Lin et al., 2005) and human (Qin et al., 2007) ES cells following DNA damage by binding to the NANOG 
promoter, and suppressing NANOG expression, implying that TP53 does translocate into the nucleus of ES cells 
following DNA damage.  Our data demonstrate that TP53 is stabilized in irradiated human ES cells.  The 
observation that both ATM kinase dependent TP53-serine 15, and ATM and CHEK2 dependent TP53-serine 20 
phosphorylation are maximal two hours following irradiation, prior to maximal TP53 protein level four hours after 
irradiation, is consistent with a function of these two kinases in TP53 stabilization and activation.  Furthermore, our 
results conclusively demonstrate that TP53 is nuclear in irradiated human ES cells. 
Mouse (Hong and Stambrook, 2004) and non-human primate (Fluckiger et al., 2006) ES cells, as well as 
human EC cells (Wang et al., 2009), have been shown to lack DNA damage induced G1 cell cycle arrest.  Here we 
extend this finding to human ES cells.  Flow cytometry revealed that irradiated human ES cells do not accumulate in 
G1 but rather at the G2/M stage of the cell cycle.  However, this cell cycle arrest is temporary, and human ES cells 
re-enter the cell cycle approximately 16 hours after irradiation.  Interestingly, in spite of the numerous similarities 
between ES and EC cells, human ES cells do not exhibit S phase delay as do human EC cells, and undergo G2/M 
arrest much earlier in comparison to human EC cells. 
Studies with histone H3-serine 10 immunocytochemistry demonstrated that human ES cells promptly cease 
mitosis, further indicating that cells are arresting in G2.  Twenty four hours following irradiation, a four fold higher 
proportion of mitotic figures appear aberrant in comparison to non-irradiated cells.  It is unclear based on these 
results why aberrant mitoses are observed.  It is possible that human ES cells resume cycling before all DNA 
damage is removed.  However, this speculation is not supported by our γ-H2AX data, because the number of 
positive foci returns to near baseline levels by 24 hours.  In addition, defective DNA DSB repair would increase 
DNA defects at mitosis such as chromosomal cross bridges.  We do not observe this phenotype, and instead see 
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numerous types of defects including spindle pole abnormalities suggesting perhaps other cell cycle errors.  
Additional experiments will be required to discern the cause of these abnormal mitotic structures.   
In order to determine if the observed accumulation of irradiated human ES cells in G2 was ATM dependent, 
we employed a selective small molecule competitive ATM inhibitor, KU55933 (Hickson et al., 2004).  KU55933 
inhibits ATM kinase activity in all somatic cells examined to date when included into culture medium at a 
concentration of 10 μM (Hickson et al., 2004; White et al., 2008).  Interestingly, we observed that a concentration of 
100 μM KU55933 is necessary in human ES cells to inhibit ATM function, as determined by ATM-serine 1981, 
CHEK2-threonine 68, and NBS1-serine 343 phosphorylation, as well as TP53 stabilization.  The partial inhibition of 
ATM kinase with 10 μM KU55933 is not due to insufficient time for inhibition, because White at al. (White et al., 
2008) reported that ATM can be inhibited within five minutes of drug addition to the medium.  It is of importance to 
note that even at 100 μM concentration KU55933 specifically targets ATM, and not other members of PI3K-related 
kinase family (Hickson et al., 2004).  One possible explanation for this difference between human ES and somatic 
cells is high expression level of multi drug resistance proteins in ES cells, which could efficiently remove the drug 
from human ES cells.  This is of particular importance for the potential use of KU55933 as a radiosensitizing drug in 
anti-cancer therapy, since an implication may be that cancer stem cells may not be radiosensitized with 10 μM 
KU55933. 
We demonstrated an essential role of ATM in induction of G2/M arrest in irradiated human ES cells.  
Following inhibition of ATM, we observed an escape of irradiated cells from G2/M arrest.  However, abrogation of 
the G2/M checkpoint was not 100% effective, as the mitotic index two hours following irradiation of KU55933 
treated human ES cells was not restored to the levels observed in non-irradiated KU55933 treated cells.  Two 
explanations are possible for this observation: 1) ATM kinase activity and signaling are not completely inhibited 
with 100 μM KU55933, or 2) there are two independent checkpoint mechanisms in human ES cells.  The 
observation that ATM kinase dependent phosphorylation of CHEK2, NBS1 and TP53 was entirely abrogated in 100 
μM KU55933 treated irradiated human ES cells suggests that a second, ATM independent G2/M checkpoint is 
operating in human ES cells.  However, additional experiments will be required in order to identify this mechanism. 
Finally, we characterized the cells that escape G2/M arrest following KU55933 treatment, and enter mitosis 
two hours following irradiation.  We detected two fold higher frequency of mitotic errors, in particular anaphase 
bridges, in comparison to KU55933 treated control cells.  At this time point γ-H2AX foci are still numerous and 
DNA DSB are not completely removed; the presence of free chromosome ends provides conditions in which 
chromosome cross links and anaphase bridges can occur, explaining the high rate of mitotic errors in these 
conditions. 
It is interesting that while ATM dependent signaling in human ES cells appears indistinguishable from that 
in human somatic cells, ATM dependent cell cycle arrest in G1 phase does not occur in ES cells.  Canonically, 
maintenance of G1/S arrest is dependent upon up-regulation of CDKN1A by TP53.  Mouse ES cells have been 
shown to lack this TP53-Cdkn1A axis (Hong and Stambrook, 2004), which explains the absence of G1/S arrest in 
these cells.  However, it is not clear whether human ES cells induce CDKN1A in response to DNA damage.  Qin et 
al. reported the absence of CDKN1A gene up-regulation following UV irradiation, but noticed a two fold increase in 
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protein level (Qin et al., 2007).  In contrast, Becker et al. demonstrated 250-300 fold induction of CDKN1A mRNA 
levels following irradiation with five grays of ionizing radiation (Becker et al. 2007).  In our data, CDKN1A protein 
was undetectable in non-irradiated human ES cells, and we observed only weak induction of protein following two 
grays of γ-irradiation.  Taken together, it is possible that human ES cells have extremely low basal levels of 
CDKN1A, and following DNA damage induce CDKN1A, but at levels that are insufficient to inhibit CDK2 activity 
in ES cells. 
It has been suggested that the G1 phase of the cell cycle is a time when ES cells are sensitive to 
differentiating cues from the environment, and that shortening of G1 can protect ES cells from differentiation 
(Lukaszewicz et al., 2005; Mummery et al., 1987).  Therefore, by escaping G1/S arrest following DNA damage, ES 
cells might be reducing the risk of differentiation.  Indeed, Maimets et al. recently demonstrated that activation of 
TP53 by nutlin induces rapid differentiation of human ES cells by promoting accumulation of cells in G0/G1 phase 
in CDKN1A dependent manner (Maimets et al., 2008).  Another possibility is that ES cells prefer repairing DNA 
damage during G2 when the sister chromatid is present allowing for error-free DNA repair by homologous 
recombination, rather than error prone non-homologous end joining.  Under this hypothesis, cells that are in G0/G1 at 
the time when DNA damage is inflicted may undergo differentiation or apoptosis, and those cells that are in G2 
phase of the cell cycle would arrest and attempt repair of the damage.  Further experiments need to be performed to 
test this hypothesis, as the kinetics and efficiency of DSB repair in human ES cells are unknown. 
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4.0  CHEKPOINT SIGNALING AND DNA DOUBLE STRAND REPAIR IN HUMAN PLURIPOTENT 
STEM CELLS 
This chapter is submitted as a research article in PLoS ONE: 
DNA DamageRresponses in Human Induced Pluripotent Stem Cells and Embryonic Stem Cells.  Olga 
Momcilovic1, 2, Leah Knobloch3, Jamie Fornsaglio3, Sandra Varum2, 4, Charles Easley2, 5, Gerald Schatten2, 5.  
1Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA, 
2Pittsburgh Development Center, University of Pittsburgh, Pittsburgh, PA, USA, 3Natural Health Sciences, Seton 
Hill University, Greensburg, PA, USA, 4Centro de Neurociências e Biologia Celular, Departamento de Zoologia, 
Universidade de Coimbra, Portugal, 5Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh 
School of Medicine, Pittsburgh, PA, USA. 
4.1 ABSTRACT 
Induced pluripotent stem (iPS) cells have the capability to undergo self-renewal and differentiation into all somatic 
cell types.  Since they can be produced through somatic cell reprogramming, which uses a defined set of 
transcription factors, iPS cells represent important sources of patient-specific cells for clinical applications. 
However, before these cells can be used in pharmaceutical or therapeutic designs, it is essential to understand their 
genetic stability, in particular because currently available iPS cells are produced using integrating viral vectors that 
carry risks of insertional mutagenesis. In this paper, we describe DNA damage responses in human iPS cells.  We 
observe hypersensitivity to DNA damaging agents resulting in rapid induction of apoptosis following γ-irradiation.  
Following radiation exposure, iPS cells activate checkpoint signaling, as evidenced by phosphorylation of ATM, 
NBS1, CHEK2, and TP53, including localization of ATM to the double strand breaks (DSB) and TP53 to the 
nucleus of NANOG-positive cells. We demonstrate that iPS cells arrest cell cycle progression in the G2 phase of the 
cell cycle, and display a similar lack of the G1/S cell cycle arrest as human embryonic stem cells.  The cell cycle 
arrest is temporary and by 24 hours post-irradiation cell cycle distribution is comparable to untreated cells.  We 
further show that both cell types remove DSB within six hours of γ-irradiation and form RAD51 foci, a surrogate 
marker for homologous recombination repair (HRR).  Repair of DSB by homologous recombination is also 
confirmed by sister chromatid exchanges after induction of DSB by 100 nM camptothecin.  Finally, our results show 
 60 
elevated expression of genes involved in DNA damage signaling, checkpoint function, and repair of various types of 
DNA lesion in ES and iPS cells relative to their differentiated counterparts.  Together, our results reveal high 
degrees of similarity in DNA damage responses between these two types of pluripotent stem cells, and also suggest 
that reprogramming significantly alters the DNA damage response of iPS cells relative to their somatic parent line. 
4.2 INTRODUCTION 
Induced pluripotent stem (iPS) cells are produced by reprogramming somatic cells with a defined set of 
transcriptional factors.  They share numerous characteristics with embryonic stem (ES) cells, such as the ability to 
undergo self-renewal and differentiation, as well as expression of the same pluripotency markers NANOG, OCT4,  
SOX2 and SSEA-4 (Takahashi and Yamanaka, 2006). Therefore, it is possible to envision numerous therapeutic 
applications for human iPS cells without the ethical challenges involved with human ES cells.  
Studies in mouse and human somatic cell reprogramming utilized four transcription factors carried on 
integrating retroviral vectors.  Two cocktails of transcription factors were successfully used: OCT4, SOX2, KLF4 
and MYC (Takahashi et al., 2007; Takahashi and Yamanaka, 2006), or OCT4, NANOG, SOX2 and LIN28 (Yu et al., 
2007).  OCT4, SOX2 and NANOG are master transcriptional regulators of the pluripotent state in embryonic stem 
(ES) cells (Chambers et al., 2003; Hart et al., 2004; Mitsui et al., 2003; Nichols et al., 1998).  These three 
transcription factors bind to and activate expression of genes that are involved in maintaining pluripotency, while 
repressing genes involved in differentiation (Boyer et al., 2005).  OCT4, SOX2, and NANOG also bind to and 
activate their own genes, creating a positive feedback loop that might “jumpstart” reprogramming (Hochedlinger 
and Plath, 2009).  However, MYC, LIN28 and KLF4 have oncogenic properties and might activate tumor 
suppression response when expressed in somatic cells.  These responses consist of cell cycle arrest, senescence and 
apoptosis, and may act as a roadblock to reprogramming.  Indeed, reprogramming is a very inefficient process with 
0.01 – 0.1% success rate (Okita et al., 2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006), suggesting 
that there are unknown limiting steps necessary for the generation of iPS cells.  Low efficiency of somatic cell 
reprogramming can be partially explained by the activation of TP53 pathway and INK4/ARF locus by 
reprogramming factors.  In fact, genetic impairment of TP53 and CDKN1A (p21) levels, as well as INK4/ARF locus 
dramatically increase efficiency of generation of iPS clones, endowing almost every somatic cell with the potential 
to form an iPS clone (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Utikal et al., 2009).   
Introduction of transcription factors also increases the γ-H2AX foci (Kawamura et al., 2009), which are 
markers of double strand breaks. Thus, it is possible that TP53 is activated following expression of reprogramming 
factors by DNA damage, and that oncogenes block reprogramming by activating DNA damage responses.   
Since genetic manipulation of TP53 or INK4/ARF locus significantly increases the efficiency of 
reprogramming, it has been suggested that reprogramming could potentially depend on rare spontaneous mutations 
or epigenetic silencing of INK4/ARF or TP53(Deng and Xu, 2009).  Another potential explanation is that activation 
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of TP53 by damaged DNA prevents the generation of iPS cells with damaged DNA or DNA repair deficiencies 
(Deng and Xu, 2009).  Taking into account the critical role of TP53 in mediating DNA damage response and tumor 
suppression, it is critical to investigate the function of TP53 and DNA damage response in iPS cells.  
Embryonic stem cells are pluripotent cells that are isolated from the inner cell mass (ICM) of the blastocyst 
(Thomson et al., 1998).  They represent the in vitro counterpart of cells that in developing embryo contribute to 
embryo proper and some extraembryonic tissues.  Similar to cells of the early embryo, ES cells are rapidly dividing.  
The cell cycle in ES cells is shortened in comparison to somatic cells, mainly due to an abbreviated G1 phase and 
facilitated G1 to S transition (Becker et al., 2006).  Rapid progression through successive rounds of DNA replication 
and mitotic division may expose ES cells to increased risk of replication errors, which are the most common source 
of double strand breaks (DSB) in proliferating cells.  Double strand breaks can also be induced by various physical 
(ionizing radiation) and chemical (radiomimetic drugs) agents and represent the most difficult type of DNA damage 
to repair.   
Following introduction of DNA damage, cells elicit a complex DNA damage response comprised of 
coordinated cell cycle arrest, DNA repair, and in some instances apoptosis.  We have previously shown that human 
ES cells activate ataxia telangiectasia mutated (ATM)-dependent checkpoint signaling cascade, including 
phosphorylation and nuclear localization of TP53 and arrest in the G2/M stage of the cell cycle following irradiation 
(Momcilovic et al., 2009).  In this study we extend these findings to iPS cells and focus on understanding the DNA 
damage response of iPS cells.  We investigated activation of checkpoint signaling and induction of cell cycle arrest 
following exposure of iPS cells to γ-radiation.  We further examined double strand break (DSB) repair and contrast 
the response of iPS cells to ES cells.  Finally, we compared the expression of DNA damage signaling and repair 
gene and protein levels between ES, iPS and differentiated cells.  Our results show that reprogramming significantly 
alters the DNA damage response in iPS cells relative to their parent line, resulting in loss of the G1/S checkpoint and 
a dramatic increase in radiosensitivity. Furthermore, iPS cells share numerous similarities in DNA damage response 
with ES cells, including G2/M cell cycle arrest, efficient DSB repair, and high expression of DNA damage signaling 
and repair genes. 
4.3 RESULTS 
4.3.1 Pluripotency and radiosensitivity in human induced pluripotent stem cells 
Induced pluripotent stem (iPS) cells share numerous similarities with embryonic stem (ES) cells, including self-
renewal, differentiation into all three germ layers, and expression of markers found in ES cells, such as OCT4, 
NANOG, SOX2, SSEA-3 and SSEA4 (Takahashi et al., 2007).  In order to confirm that we are investigating DNA 
damage response of pluripotent cells we examined expression of pluripotency markers NANOG, SSEA4 and OCT4 
in both untreated cells and cells irradiated with one Gray (Gy) of γ-irradiation (Figure 14).  We decided to use 
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NANOG and SSEA4 as markers of pluripotency because they were not used in the reprogramming cocktail to derive 
the AE iPS line.  Furthermore, in the extremely remote case that irradiation reactivates the reprogramming factors, 
NANOG and SSEA4 would still reflect expression of endogenous genes.  Both the untreated cell population and 
those exposed to radiation treatment show expression (Figure 14A) and nuclear localization of NANOG (Figure 
14B), as well as cell surface expression of SSEA4 (Figure 14C), suggesting that, similar to human ES cells, iPS cells 
retain pluripotency markers after acute induction of DNA damage.  We did not detect decreases in OCT4 protein 
levels by Western blot analysis (Figure 14A), confirming these results. 
Figure 14:  Pluripotency and radiosensitivity of human induced pluripotent stem (iPS) cells.  
 63 
(A): Western blot analysis of NANOG and OCT4 after irradiation. β-actin served as the loading control. (B): 
Confocal microscopy for NANOG in iPS cells at indicated time periods after irradiation. Inset – zoomed region of a 
colony displaying nuclear localization of NANOG. Green – NANOG, Blue – DNA, scale bar = 100 µm (20 µm 
inset). (C): Confocal microscopy for SSEA4 in iPS cells at indicated time period after irradiation. Green – SSEA4, 
Blue – DNA, scale bar = 20 µm. (D): Western blot analysis for cleaved caspase-3 after irradiation. Human iPS cells 
were irradiated, or left untreated, returned to incubator and recovered for indicated periods of time. Adherent and 
detached cells were collected and analyzed separately. β-actin served as the loading control. 
 
Human and mouse ES cells exhibit profound sensitivity to DNA damaging agents (Aladjem et al., 1998; 
Momcilovic et al., 2009).  We also noted significant detachment of iPS cells from the surface of the cell culture dish 
by 24 hours following irradiation (Figure 14B), even when a radiation dose of one Gy was used.  To confirm that 
cells were indeed undergoing cell death we performed Western blot analysis for cleaved caspase-3, including both 
adherent and detached (floating) cells (Figure 14D).  Cleaved caspase-3 began to appear four hours after irradiation 
in adherent cells and continued to increase for 24 hours, particularly in the detached cells, suggesting that iPS cells 
undergo apoptosis. 
4.3.2 Activation of checkpoint signaling in irradiated human induced pluripotent stem cells 
Following introduction of double strand breaks (DSB) ATM undergoes auto-phosphorylation at serine 1981 and its 
kinase function is activated, leading to phosphorylation of numerous downstream targets (Abraham, 2001; Bakkenist 
and Kastan, 2003).  We have previously demonstrated that ATM is phosphorylated at serine 1981 and localizes to 
DSB sites within 15 minutes of γ-irradiation in human ES cells (Momcilovic et al., 2009).  We tested activation of 
ATM-dependent checkpoint signaling cascade in two iPS lines by Western blot (Figure 15A) and 
immunocytochemistry (Figure 15B, C) after one (Figure 15) and two Gy of γ-irradiation (Figure 16A).  Both 
dosages induced strong checkpoint signaling response as evidenced by phosphorylation of ATM and its target 
proteins.  Western blot analysis revealed ATM-serine 1981, CHEK2-threonine 68, NBS1-serine 343, and TP53-
serine 15 phosphorylation within one hour of γ-irradiation.  ATM-serine 1981 and CHEK2-threonine 68 
phosphorylation was highest one hour after irradiation and declined subsequently, staying above steady-state level 
six hours later.  NBS1-serine 343 phosphorylation peaked four hours after irradiation, returning to steady-state levels 
six hours following irradiation.  ATM-dependent phosphorylation of TP53 at serine 15 was highest two hours after 
irradiation, and declined four hours post irradiation. During the same time period the level of total ATM, CHEK2 
and NBS1 proteins did not change, whereas the level of total TP53 protein increased following TP53 
phosphorylation, suggesting that TP53 is stabilized in response to radiation-induced DNA damage (Chehab et al., 
1999; Tibbetts et al., 1999).  We also investigated localization of ATM-serine 1981 and TP53-serine 15 in response 
to radiation exposure.  Phosphorylated ATM was localized to sites of DNA damage as detected by co-localization 
with DSB marker γ-H2AX (Figure 15B). Furthermore, in order to confirm that we were observing the DNA damage 
response in pluripotent stem cells, we co-stained iPS cells with TP53-serine 15 and NANOG (Figure 15C), and 
detected nuclear localization of TP53-serine 15 in NANOG-positive cells after irradiation.  Additionally, we 
compared expression of TP53 target genes between non-irradiated and irradiated iPS cells (Figure 15D).  We 
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detected two-fold or greater upregulation of genes involved in cell cycle arrest: p21 (CDKN1A), GADD45A, 
PPM1D, SESTRIN1 (SESN1), SESTRIN2 (SESN2), and MDM2, suggesting that TP53 is transcriptionally activated 
after irradiation.  Interestingly, we did not detect upregulation of TP53-dependent apoptosis genes BAX and BCL2. 
Collectively, these results are very similar to our previous observations in human ES cells and confirm activation of 
checkpoint signaling cascade in iPS cells following exposure to one and two Gy of γ-irradiation. 
 
Figure 15:  Activation of checkpoint signaling cascade in human induced pluripotent stem (iPS) cells.  
(A): Western blot analysis of ATM-serine 1981, total ATM, CHEK2-threonine 68, total CHEK2, NBS1-serine 343, 
total NBS1, TP53-serine 15, and total TP53 at indicated time points after γ-irradiation of iPS cells. β-actin served as 
the loading control.  (B): Confocal microscopy for ATM and γ-H2AX in iPS cells at indicated time points after 
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irradiation. Green – ATM-serine 1981, Red – γ-H2AX, Blue – DNA, Yellow – co-localization of ATM-serine 1981 
and γ-H2AX. Scale bar = 10 µm. (C): Confocal microscopy for NANOG and TP53-serine 15 in irradiated iPS cells 
at indicated time points after irradiation. Green – NANOG, Red – TP53-serine 15, Blue – DNA. Scale bar = 10 µm. 
(D): Expression of TP53 target genes in irradiated human induced pluripotent stem (iPS) cells.  Fold changes were 
calculated using the -ΔΔCt method relative to non-irradiated iPS cells and normalized using ACTB as endogenous 
control. 
Figure 16:  Activation o f checkpoint s ignaling cascade a nd c ell c ycle a rrest i n hum an i nduced pl uripotent 
stem (iPS) cells following 2 Grays of γ-irradiation.  
(A): Western blot analysis of ATM-serine 1981, total ATM, CHEK2-threonine 68, total CHEK2, NBS1-serine 343, 
total NBS1 and TP53-serine 15 at indicated time points after γ-irradiation of iPS cells. β-actin served as the loading 
control.  (B): Confocal microscopy for phospho-histone H3 after irradiation of human iPS cells.  Red – phospho-
histone H3, Blue – DNA. Scale bar = 10 µm. 
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4.3.3 Cell cycle arrest in irradiated human induced pluripotent stem cells 
 We next investigated whether iPS cells arrest in response to ionizing irradiation, and if so at which stage of the cell 
cycle. We employed flow cytometric analysis of DNA content using PI in order to monitor progression of irradiated 
iPS cells through the cell cycle (Figure 17A).  As expected of self-renewing pluripotent cells, a high percentage of 
non-irradiated iPS cells were in S phase (Table 11).  After exposure to one Gy of γ-irradiation, iPS cells arrested in 
Figure 17:  Induction of a temporary G2/M cell cycle arrest in irradiated human induced pluripotent stem (iPS) cells.  
(A): Analysis of DNA content of irradiated human iPS cells by flow cytometry using PI. Top panel: DNA histograms displaying 
cell cycle profiles measured 0 – 24 hours after irradiation. Bottom panel: percentages of cells in G1, S, and G2/M phase of the 
cell cycle at indicated time points after irradiation.  Percentages were calculated using ModFit software (Verity Software 
House).  Results were gated to exclude cellular debris, sub-G0 population, and doublets.  Data present mean ± SEM calculated 
from three independent experiments.  (B): Confocal microscopy for phospho-histone H3 after irradiation of human iPS cells.  
Green – phospho-histone H3, Blue – DNA. Scale bar = 10 µm.  (C): Quantification of mitotic indexes in non-irradiated cells 
and 24 hours after irradiation.  At least 500 cells per condition were counted in three independent experiments, and statistical 
difference was determined with χ2 test.  The data represent mean ± SEM.   (D): Examples of normal (top row) and aberrant 
(bottom row) mitotic figures visualized by confocal microscopy after staining for mitotic marker phospho-histone H3.  
Abbreviations: A – anaphase, M – metaphase, P – prophase, T – telophase. Arrow – lagging chromosome, plus sign – 
misaligned chromosome, asterisks – pole of mitotic spindle. Green – phospho-histone H3, Red – β-tubulin, Blue – DNA. Scale 
bar = 10 µm. 
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the G2/M stage of the cell cycle, displaying a similar absence of G1/S cell cycle arrest as mouse, non-human primate 
and human ES cells (Fluckiger et al., 2006; Hong and Stambrook, 2004; Momcilovic et al., 2009).  Three hours after 
irradiation a significant drop in the percentage of cells in G1 phase was observed, whereas percentage of cells in 
G2/M increased.  This trend continued for six hours after irradiation, and by nine hours after irradiation the majority 
of cells (77%) were in G2/M phase.  By 24 hours post-irradiation, cell cycle distribution resembled non-irradiated 
cells (Table 11, Figure 17A). 
Table 11:  Percentage of cells at each stage of the cell cycle (mean ± SEM) 
 Non-Irradiated 3 hrs 6 hrs 9 hrs 24 hrs 
G1 26.8±3.8 15.3±3 9.2±4.4 7.6±3.7 24.4±3.5 
S 60±4.5 57.5±3.1 43.1±1.4 15.7±8.2 27.2±0.9 
G2/M 13.2±1.2 27.3±1.5 48.6±3.1 76.7±5 48.4±3.6 
In order to better understand when cells arrest after irradiation (G2 or M phase), as well as the events that 
occur following iPS cells' return to the cell cycle, we performed immunocytochemistry using mitosis-specific 
marker histone H3 phosphorylated at serine 10 (phospho-H3).  In a population of non-irradiated cells we observed 
numerous phospho-H3-positive cells in various stages of mitosis (Figure 17B).  Twenty minutes after exposure to 
one (Figure 17B) or two Gy (Figure 16B) of γ-radiation we still observed mitotic cells, presumably cells that were 
already undergoing mitosis at the time of irradiation.  However, two, four, and six hours after irradiation, we could 
not detect any mitotic cells, suggesting that iPS cells arrest in the G2 phase and do not enter mitosis following 
irradiation.  Mitotic cells start reappearing 24 hours after irradiation (please see Figure 17D for examples), with no 
statistically significant difference in mitotic index (5.1 ± 0.34%; Figure 17C) compared to non-irradiated cells (4.3 ± 
0.48%; n=3, 0.3>p>0.2). Note that a lot of cellular debris is present in cell colonies both at 6 and 24 hours after 
irradiation, in accordance with iPS cells’ radiosensitivity.  In aggregate, both flow cytometry and 
immunocytochemistry results reveal that iPS cells arrest in G2 stage of the cell cycle and resume cell cycle 
progression by 24 hours following irradiation. 
4.3.4 Double strand break repair in human embryonic stem and induced pluripotent stem cells 
The fact that iPS cells resume the cell cycle within 24 hours of DNA damage suggests that DNA breaks are removed 
by that time and allowing recovery from the cell cycle arrest.  We investigated DSB repair by monitoring formation 
and removal of γ-H2AX foci, which is frequently used as a DSB marker.  Since open chromatin structure can lead to 
formation of microscopically visible foci in the absence of exogenous DNA damage (Banath et al., 2009) and since 
both human ES and iPS cells have open chromatin structure, we first tested the usefulness of γ-H2AX as a DSB 
marker in human ES cells by inducing localized damage.  We employed a 405 nm laser to induce DNA damage in a 
specified nuclear region of several ES cells in the colony, as well as in several mouse embryonic fibroblasts (MEF) 
that were used to co-culture human ES cells (Figure 18).  Thirty minutes after laser treatment, we detected γ-H2AX 
in MEF but only in affected cells and only in the nuclear region that was targeted, confirming our goal behind γ-
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H2AX testing.   In human ES cells we also detected DNA damage only in cells of colonies that were treated with the 
laser, and not in neighboring cells.  However, unlike in MEF cells, γ-H2AX staining was not confined to the affected 
nuclear region; instead, staining was present in the whole nucleus (Figure 18), perhaps due to highly dynamic 
chromatin in pluripotent stem cells (Meshorer et al., 2006).  Nevertheless, we confirmed that γ-H2AX staining is 
sensitive enough to detect DNA damage only in laser-treated human ES cells.  
We irradiated human ES and iPS cells with one Gy of γ-irradiation and performed time-course 
immunocytochemistry for γ-H2AX (Figure 19).  Non-irradiated human ES and iPS cells were not completely void 
of γ-H2AX foci, which may reflect endogenous DNA damage.  However, within 20 minutes of γ-irradiation we 
detected strong induction of γ-H2AX foci in both cell types. Over the following four hours, both cell types lost many 
of these foci, so that by six hours post irradiation the number of γ-H2AX foci had returned to steady-state levels.   
Two main pathways for DNA repair include error-prone non-homologous end joining (NHEJ) and error-
free homologous recombination repair (HRR).  Unlike NHEJ, HRR relies on the presence of the sister chromatid for 
use as a template for accurate DNA repair, and is hence limited to late S and G2 phases of the cell cycle.  We 
hypothesized that HRR plays a major role in DSB repair in ES cells due to their developmental role and the 
requirement that their genomic integrity be preserved, as well as the fact that, in any given moment, more than 70% 
of an ES cell population is in the S and G2/M phases of the cell cycle (Momcilovic et al., 2009), when the sister 
chromatid is available.  In order to test this, we irradiated ES and iPS cells with one Gy of γ-radiation and 
investigated the formation of RAD51 foci (Figure 20A).  RAD51 is a recombinase that is essential for HRR and, 
following induction of DSB, localizes to the foci that are believed to represent sites where HRR takes place.  Two 
hours following irradiation we detected formation of RAD51 foci in the majority of cells suggesting that both ES 
and iPS cells repair DSB by HRR.  Even more direct evidence of HRR are the sister chromatid exchanges (SCE) 
that represent a subset of HRR events.  We treated ES and iPS cells with 50 and 100 nM camptothecin for one hour 
Figure 18:  Induction of localized DNA damage in mouse embryonic fibroblasts (MEF) and human embryonic stem (ES)
cells.   
405 nm laser was used at 25% intensity to induce DNA damage in defined nuclear region of MEF and hESC.  Thirty minutes 
following DNA damage, cells were fixed and stained for double strand break marker γ-H2AX.  Green – γ-H2AX, Blue – DNA. 
Scale bar = 10 µm. 
 
 69 
to induce breaks in S-phase cells (Figure 20B).  Camptothecin is a topoisomerase I inhibitor that stabilizes the 
topoisomerase I – DNA complex.  Topoisomerase I-introduced single strand nicks in DNA can be converted into 
DSB if the replication fork collides with stabilized topoisomerase I – DNA complex.  Therefore, camptothecin 
specifically introduces DSB in replicating cells, eliciting HRR repair of DSB. We observed increase in the number 
of SCE following 50 nM and 100 nM treatments of ES and iPS cells.  The increase was similar in both cell types, 




Figure 19:  Repair o f do uble strand br eaks ( DSB) i n hum an e mbryonic s tem ( ES) a nd i nduced pl uripotent s tem ( iPS) 
cells. 
Time course immunocytochemistry for marker of DSB γ-H2AX in ES cells (left panel) and iPS cells (right panel).  Green – γ-
H2AX, Blue – DNA. Scale bar = 10 µm. 
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Figure 20:  Homologous recombination repair in human stem (ES) and induced pluripotent stem (iPS) cells.   
(A): Confocal microscopy for RAD51 in irradiated human ES cells (left panel) and iPS cells (right panel).  Green – RAD51, Blue 
– DNA.  Scale bar = 10 µm.  (B): Sister chromatid exchanges (SCE) in untreated and 100 nM camptothecin treated human ES 
cells (left panel) and iPS cells (right panel).  Cells were grown for one cell cycle in the presence of 10 µM BrdU, followed by one 
hour treatment with 100 nM camptothecin and 15 hours recovery in the fresh medium.  Following 90 minute 120 ng/ml colcemid 
treatment cells were harvested for cytogenetic preparation and differential staining with Hoechst 33258 dye and Giemsa was 
performed.  The number of reciprocal SCE was counted in 25 metaphase spreads.  
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4.3.5 Gene expression analysis in pluripotent and differentiated cells 
ES cells have been reported to have greater capacities for DNA repair as compared with somatic cells, and have 
higher expression of some DNA repair genes (Maynard et al., 2008; Tichy et al.; Tichy and Stambrook, 2008). We 
explored this finding in human ES and iPS cells by comparing the expression level of genes participating in DNA 
damage signaling, cell cycle arrest, as well as DNA repair across three human ES cell lines (WA01, WA07, WA09), 
two iPS cell lines (IMR-90 iPS, AE iPS), and two differentiated cell lines (WA07 teratoma fibroblasts [TF] and 
IMR-90 fibroblasts), using quantitative PCR (qPCR) array (Figure 21).  TF and IMR-90 served as differentiated 
counterparts for ES and iPS cell lines, respectively.  We excluded from the data analysis ten genes with Ct values 
above 30 (BTG2, CIDEA, DMC1, GADD45G, GML, IP6K3, PCBP4, RAD51, SEMA4A, TP73).  Since the ES cell 
lines did not show any significant difference in gene expression between each other (p>0.05, Figure 22), they were 
grouped together and used as a control for fold difference comparisons.  Interestingly, we also could not detect 
significant difference in gene expression between ES and iPS lines, although AE iPS line did show increased (but 
not significant) gene expression relative to ES cells (less than two fold difference, p>0.05, Figure 22).  In 
fibroblasts, however, the general trend was reduced gene expression relative to ES and iPS cells (Figure 6A).  Out of 
57 analyzed genes, 38 (66.7%) showed two-fold or greater downregulation in IMR-90, whereas 31 genes (54.4%) 
displayed two-fold or greater downregulation in TF.  In IMR-90, only two (3.5%) genes were two-fold or more 
upregulated (MPG and TREX1), while in TF three genes (5.3%) (MPG, TREX1 and GADD45A) were upregulated.  
Based on the p<0.05 cut-off, 23 genes in IMR-90 displayed a statistically significant expression fold difference and 
nine in TF.  These genes showed also at least two-fold difference in comparison to ES lines, so we considered their 
expression biologically altered.  
We grouped genes according to their pathways and gene expression fold differences relative to ES cells:  
DNA damage signaling and cell cycle arrest (Figure 21B), DSB repair (Figure 21C), MMR (Figure 21D), BER 
(Figure 21E), and NER (Figure 21F).  The corresponding p-values are shown in Tables 12 – 16. Out of 18 genes 
involved in cell cycle arrest and DNA damage signaling, seven showed statistically significant lower expression in 
IMR-90 cells (ATR, BRCA1, CHEK1, PCNA, RAD9A, SMC1A, TTP53), and one showed significant reduction in TF 
cells (ATR) while another showed increased expression (GADD45A) (Figure 21B; Table 12). In a group of 22 DSB 
repair genes, 13genes were expressed at significantly lower levels in IMR-90 (ATR, BRCA1, FANCG, FEN1, 
XRCC6(Ku70), LIG1, MRE11A, PRKDC(PRKDC), RAD18, RAD9A, RPA1, XRCC2), and five in TF (ATR, FANCG, 
FEN1, MRE11A, PRKDC(PRKDC)) (Figure 21C; Table 13).  In the group of genes involved in MMR we detected 
five genes with lower expression in IMR-90 (EXO1, MSH2, MSH3, MUTYH, N4BP2) and two in TF (MSH2, 
N4BP2), whereas TREX1 showed higher expression in TF when compared to ES cells (Figure 21D; Table 14).  
Among eight BER genes, three showed reduced expression in IMR-90 (MUTYH, UNG, XRCC1), whereas MPG 
showed increased expression in IMR-90 relative to ES cells (Figure 21 E; Table 15).  Finally, TF did not show any 
significant difference in expression of genes involved in BER, nor NER (Figure 21E, F; Table 15, 16).  But though 
there was no statistical significance in observed fold difference in gene expression, most of the analyzed genes 
showed lower expression in differentiated cells than in ES or iPS cells (Figure 21).  Thus, ES and iPS cell lines 
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display a similar expression pattern for DNA damage signaling and repair genes, and exhibit generally elevated 
expression levels compared to their differentiated counterparts, TF and IMR-90, respectively (Figure 21A).  These 
results suggest that differentiation and reprogramming significantly alter the expression pattern of DNA damage 
response genes. 
  
Figure 21:  Analysis of D NA d amage s ignaling an d r epair g ene e xpression i n hum an pl uripotent stem c ells a nd 
differentiated cells.   
(A): Heat map of transcripts analyzed by PCR array.  Expression values were normalized over the expression of β-actin and 
presented as log10 of relative changes compared to WA07.  In comparison to WA07 genes with higher expression are depicted in 
red, genes with lower expression are depicted in green, and genes with no difference are depicted in black.  Cell lines were 
clustered based on the overall similarity in gene expression.  The genes were grouped according to the pathway they participate 
in: (B): DNA damage and cell cycle arrest signaling, (C): double strand break (DSB) repair, (D): mismatch repair (MMR), (E): 
base excision repair (BER), (F): nucleotide excision repair (NER).  Expression fold differences were calculated using the -ΔΔCt 
method relative to averaged ES cell lines and normalized using ACTB as endogenous control.  The data presented are from three 
independent experiments.   
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Figure 22:  Gene expression comparison between pluripotent stem cell lines.   
Volcano plots represent p-values (Y-axis) for observed difference in gene expression (X-axis).  Blue horizontal line represents 
position of –Log10(0.05) for easier visualization of significant (p<0.05) difference.  Horizontal lines represent two fold 
boundaries: on the left are shown genes with more than twofold downregulation (green), and on the right are genes with more 
than two fold upregulation (red) in comparison to control line. Genes in between vertical lines show less than two fold difference 
in gene expression and are depicted in black.  Dots represent genes on the array.  
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Table 12:  p-value comparing to ES cell expression: DNA damage signaling and cell cycle arrest genes.  
Gene IMR-90 iPS AE iPS IMR-90 TF 
ATM 0.57631 0.506295 0.085474 0.298853 
ATR 0.224651 0.136748 0.00012 0.007757 
BRCA1 0.696705 0.80286 0.039688 0.173745 
CCNH 0.94397 0.428333 0.224058 0.853943 
CDK7 0.955632 0.259967 0.819881 0.682147 
CHEK1 0.987316 0.118751 0.031091 0.103799 
CHEK2 0.859196 0.844377 0.054215 0.106662 
GADD45A 0.328035 0.92211 0.183808 0.045834 
GTSE1 0.648524 0.406655 0.069732 0.255467 
HUS1 0.960966 0.949327 0.059013 0.309369 
MNAT1 0.955009 0.478443 0.255932 0.611328 
PCNA 0.850991 0.233539 0.023314 0.121541 
RAD1 0.771902 0.536311 0.291469 0.20101 
RAD17 0.955772 0.473923 0.120408 0.406977 
RAD9A 0.597626 0.537845 0.023091 0.122588 
RBBP8 0.824502 0.345977 0.084385 0.28663 
SMC1A 0.737524 0.272268 0.049401 0.094141 
TTP53 0.773965 0.377934 0.023513 0.098894 
 
Table 13:  p-value comparing to ES cell expression: DSB repair genes. 
Gene IMR-90 iPS AE iPS IMR-90 TF 
ABL1 0.949231 0.549173 0.504224 0.452685 
ATM 0.57631 0.506295 0.085474 0.298853 
ATR 0.224651 0.136748 0.00012 0.007757 
BRCA1 0.696705 0.80286 0.039688 0.173745 
FANCG 0.947707 0.562551 0.005944 0.042056 
FEN1 0.398639 0.310912 0.000734 0.015698 
XRCC6 (Ku70) 0.943276 0.654172 0.033858 0.123937 
XRCC6BP1 0.754221 0.505813 0.069761 0.389662 
LIG1 0.930717 0.546939 0.011995 0.067929 
MRE11A 0.413568 0.515739 0.019145 0.046147 
NBN (NBS1) 0.973539 0.711284 0.053436 0.543504 
PRKDC (DNA-PKcs) 0.821906 0.694589 0.00513 0.029441 
RAD1 0.771902 0.536311 0.291469 0.20101 
RAD17 0.955772 0.473923 0.120408 0.406977 
RAD18 0.995641 0.545698 0.04567 0.203224 
RAD21 0.916088 0.790471 0.071021 0.223934 
RAD50 0.824122 0.711063 0.185977 0.696658 
RAD51L1 0.982636 0.809205 0.084185 0.331463 
RAD9A 0.597626 0.537845 0.023091 0.122588 
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RPA1 0.735362 0.536414 0.023445 0.072859 
XRCC2 0.573091 0.769153 0.027158 0.066824 
XRCC3 0.325782 0.994872 0.834946 0.68676 
 
Table 14:  p-value comparing to ES cell expression: MMR genes. 
Gene IMR-90 iPS AE iPS IMR-90 TF 
ABL1 0.949231 0.549173 0.504224 0.452685 
ANKRD17 0.934429 0.731614 0.09786 0.204471 
EXO1 0.492576 0.522098 0.031245 0.095152 
MLH1 0.416364 0.465582 0.081946 0.23796 
MLH3 0.997759 0.965141 0.174521 0.328437 
MSH2 0.857991 0.435612 0.023702 0.060512 
MSH3 0.869539 0.269519 0.041186 0.430153 
MUTYH 0.451588 0.259017 0.016515 0.056259 
N4BP2 0.864914 0.672229 0.009036 0.031524 
PMS1 0.937467 0.754491 0.081887 0.186824 
PMS2 0.292682 0.415731 0.641265 0.838477 
PMS2L3 0.725087 0.863888 0.818104 0.401013 
TREX1 0.916034 0.528133 0.191454 0.035572 
 
Table 15:  p-value comparing to ES cell expression: BER genes. 
Gene IMR-90 iPS AE iPS IMR-90 TF 
APEX1 0.881701 0.216286 0.085594 0.381403 
MBD4 0.877766 0.361172 0.267382 0.230659 
MPG 0.487583 0.456759 0.011145 0.068083 
MUTYH 0.451588 0.259017 0.016515 0.056259 
NTHL1 0.815198 0.135108 0.063159 0.177981 
OGG1 0.816398 0.570708 0.116337 0.49135 
UNG 0.540893 0.21115 0.033375 0.078898 
XRCC1 0.811104 0.168127 0.029069 0.152095 
 
Table 16:  p-value comparing to ES cell expression: NER genes. 
Gene IMR-90 iPS AE iPS IMR-90 TF 
ERCC1 0.467596 0.353567 0.240213 0.29478 
ERCC2 0.3228 0.588618 0.124794 0.314321 
RPA1 0.735362 0.536414 0.023445 0.072859 
XPA 0.949872 0.933206 0.673024 0.879367 
XPC 0.808056 0.690012 0.256061 0.601866 
XRCC1 0.811104 0.168127 0.029069 0.152095 
 
Table 13 continued. 
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We also validated gene expression data by comparing DSB repair protein levels between human ES, iPS 
and differentiated cell lines (Figure 23). We detected a lower level of proteins involved in HRR (MRE11, NBS1 and 
RAD52) and NHEJ (XRCC4 and ligase IV) in TF and IMR-90 compared to ES and iPS cells, thereby confirming 
our gene expression results. 
4.4 DISCUSSION 
In this study we set forth to investigate DNA damage response, including checkpoint signaling, cell cycle arrest, 
apoptosis and DNA repair in iPS cells. We found that overall response of iPS cells to ionizing radiation is very 
similar to that in human ES cells.  Following activation of the ATM-dependent checkpoint signaling cascade by 
Figure 23:  Comparison of DNA repair protein levels between pluripotent stem cells and differentiated cells.   
Western blot analysis of basal level of proteins involved in homologous recombination, non-homologous end joining, and 
pluripotency maintenance.  α-tubulin served as the loading control. 
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ionizing radiation, iPS cells arrest cell cycle progression in G2 phase.  Furthermore, keeping in mind that DSB repair 
efficiently removes DNA breaks, we present evidence for homologous recombination in human ES and iPS cells.  
More generally, human ES and iPS cells exhibit elevated expression of DNA repair genes, perhaps explaining the 
high capacity for DNA repair in human ES cells. 
Irradiation of iPS cells induced strong apoptotic response, resulting in visual loss of iPS cells from the 
colony in the 24 hours after irradiation, and increased cleavage of caspase-3 four hours following radiation treatment 
(Figure 14B, D).  We conducted initial experiments using the same two Gy dose of γ-radiation as we did for studies 
using human ES cells.  The iPS cells responded with such a high level of cell death that almost all cells had died by 
24 hours post-irradiation (data not shown).  Therefore, we limited the dosage used in this study to one Gy, which 
elicited a DNA damage response while preserving enough cells to perform experiments.  Thus, human iPS cells 
exhibit profound radiosensitivity, similar to observations in mouse, non-human primate and human ES cells 
(Aladjem et al., 1998; Fluckiger et al., 2006; Hong and Stambrook, 2004; Momcilovic et al., 2009).  We did not 
detect such a level of cell death in IMR-90 fibroblasts, the parent line for IMR-90 iPS cells (data not shown), 
suggesting that radiosensitivity is specifically associated with pluripotent state.   
We also investigated the expression of pluripotency markers NANOG, SSEA4 and OCT4 in untreated and 
irradiated iPS cells.  As expected, iPS cells show robust expression of NANOG and OCT4 proteins, nuclear 
localization of NANOG, and cell surface expression of SSEA4 (Figure 14).  Similar to previous findings in human 
ES cells, γ-irradiation does not lead to downregulation of OCT4 and NANOG protein levels during the six hours 
after irradiation, and confocal microscopy confirmed expression and appropriate localization of NANOG and 
SSEA4 up to 24 hours after DNA damage.   
We next studied activation of ATM and its target proteins, CHEK2, NBS1 and TP53, using Western blot 
analysis and confocal microscopy (Figure 15).  The kinetics of ATM, CHEK2, NBS1 and TP53 phosphorylation 
was remarkably similar to observations made in human ES cells.  In addition, we verified canonical localization of 
ATM-serine 1981 to the sites of DSB by co-localization with γ-H2AX.  In addition, double labeling of irradiated iPS 
cells with NANOG and TP53-serine 15 confirmed activation of checkpoint signaling in pluripotent cells.  Finally, 
examination of expression of TP53 target genes revealed upregulation of CDKN1A, GADD45A, SESN1, SESN2, 
MDM2 and PPM1D, indicating that TP53 is transcriptionally active.  Studies that showed that TP53 knockout 
improves reprogramming efficiency, led some authors to question the status of TP53 in iPS cells (Deng and Xu, 
2009).  Our finding suggests that TP53 is active in iPS cells and that reprogramming does not affect TP53.   
The analysis of iPS cell cycle distribution revealed a lack of G1/S arrest in irradiated iPS cells (Figure 17).  
Instead, iPS cells arrest in the G2 phase of the cell cycle, analogous to data in ES cells.  Cell cycle analysis revealed 
that reprogramming induces changes in the cell cycle structure, resulting in highly proliferative cell populations with 
60 ± 4.5% cells in the S phase, and 4.3 ± 0.5 % in mitosis, mirroring findings in the human ES cells.  Since it has 
been proposed that the G1 phase of the cell cycle is a time when ES cells are sensitive to differentiating signals, it is 
not surprising that reprogramming also leads to loss of G1/S cell cycle arrest in iPS cells, which may protect them 
from differentiation.   
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Cell cycle analysis, as well as staining for mitotic marker phospho-histone H3, showed that cell cycle arrest 
is temporary and that 24 hours after irradiation iPS cells restart cell cycle progression.  This finding suggests that 
iPS cells repair damaged DNA during this time frame.  We followed DSB repair by examining the kinetics of γ-
H2AX foci formation and removal (Figure 19).  H2AX is a histone variant that is phosphorylated at serine 139 (and 
referred to as γ-H2AX) by ATM, DNA-PK and ATR at DSB sites and covers mega base-long stretches of DNA 
surrounding the DSB (Rogakou et al., 1999; Rogakou et al., 1998).  In mouse ES cells, γ-H2AX forms visible foci 
even in the absence of externally-induced DNA damage and, following irradiation, endogenous γ-H2AX foci cannot 
be clearly distinguished from irradiation-induced foci (Banath et al., 2009).  This has been attributed to open 
chromatin structure and global chromatin decondensation that favors formation of visible γ-H2AX foci and limits 
the use of this marker in following DNA repair in mouse ES cells (Banath et al., 2009).   Since both human ES and 
iPS cells also have open chromatin structure, we first validated γ-H2AX as a DSB marker in human ES cells by 
inducing localized damage with a 405 nm laser.  We observed localized γ-H2AX staining in laser-irradiated MEF, 
but relatively spread out γ-H2AX staining in laser-treated ES cells (Figure 18).  This can be explained because of 
highly dynamic chromatin in pluripotent stem cells (Meshorer et al., 2006), so that chromatin movement distributes 
damaged DNA from a localized region throughout the nucleus; γ-H2AX staining was not observed in untreated 
MEF and ES cells, justifying the use of γ-H2AX as a DSB marker.  When we irradiated ES and iPS cells with γ-
irradiation, we observed γ-H2AX foci forming within 20 minutes of irradiation.  The foci were gone within six 
hours of irradiation, indicating that DNA repair took place within that time frame, consistent with earlier 
observations of efficient DNA repair in human ES cells (Maynard et al., 2008).  
The two main pathways for repairing DSB are homologous recombination repair (HRR) and non-
homologous end joining (NHEJ).  Homologous recombination is critically dependent on the presence of the 
homologous sequence on the sister chromatids, so it typically occurs in the late S and G2 phases of the cell cycle.  
The use of the homologous chromosome during G1 phase could lead to loss of heterozygosity and be potentially 
harmful.  The advantage of HRR is that the original DNA sequence is restored without any loss of information 
because it uses the sister chromatid as a template, making it an error-free method of repair.  In contrast, NHEJ does 
not require regions of homology and can operate in any stage of the cell cycle. However, due to the complex nature 
of DSB (non-ligatable groups, 3’ or 5’ overhangs), processing DSB without a template can likely lead to the loss of 
some genetic information.  The advantage of NHEJ is that it is fast and independent of whatever cell cycle stage the 
cell is at.  Focusing on ES cells, it has long been speculated that HRR is the predominant form of DSB repair in this 
developmentally critical cell type, and this was recently confirmed in mouse ES cells (Banuelos et al., 2008; Serrano 
et al.; Tichy et al.).  Mouse ES cells also demonstrate lower expression of key NHEJ repair factors, such as Ligase 
IV and PRKDC (Banuelos et al., 2008; Tichy et al.), and show elevated expression or HRR factors (RAD51, RAD54 
and RAD52) (Tichy et al.) compared to MEF.  Here we show evidence that human ES and iPS cells repair DSB 
through HRR, which uses RAD51 as a surrogate marker for HRR and visualization of SCE (Figure 20).  Gene and 
protein expression analysis revealed that both human ES and iPS cells have higher expression levels of factors 
involved in DNA damage signaling and DNA repair than their differentiated counterparts (Figure 21, Figure 23).  
Maynard and colleagues (Maynard et al., 2008) reported similar data in human ES cells and showed that human ES 
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cells exhibit a higher capacity for repairing multiple forms of DNA lesions. Interestingly, human ES and iPS cells 
display elevated expression of genes involved in HRR (RAD52, MRE11, NBS1) and, unlike in mouse ES cells 
(Tichy et al.), NHEJ (PRKDC, XRCC6, Ligase IV, XRCC4) relative to differentiated cells (Figure 21).  Other 
researchers also described differences in expression levels of NHEJ factors in human ES cells relative to mouse ES 
cells: human ES cells expressed higher levels of PRKDC and XRCC6 than mouse ES cells, and showed proficiency 
in end-joining, which mouse ES cells lack (Banuelos et al., 2008). Therefore, it appears that there are species-
specific differences between mouse and human ES cells regarding the roles of HRR and NHEJ.  Additionally, it 
seems there is a general difference between mouse and human somatic cells in their dependence on NHEJ.  For 
example, DNA-PK activity (Finnie et al., 1995) and XRCC6 expression (Anderson and Lees-Miller, 1992) are 
higher in human  somatic cells relative to mouse cells, and XRCC5 is an essential protein in human but not mouse 
cells (Li et al., 2002).  Nevertheless, the relative contributions and importance of HRR and NHEJ in human ES and 
iPS cells still need to be clarified. 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
Embryonic stem (ES) cells are pluripotent cells that are isolated from the inner cell mass (ICM) of the blastocyst 
(Thomson et al., 1998).  They represent in vitro counterpart of cells that in developing embryo contribute to embryo 
proper and some extraembryonic tissues.  Since ES cells inherited behavior of the ICM cells, they can be used to 
study various aspects of early development.  The two most important characteristics of ES cells are 1) capability to 
undergo self-renewal and 2) ability to differentiate into all cell types of an organism.  Self-renewal depends on the 
ability of cells to divide and replenish stem cell pool, whereas pluripotency depends on plasticity of cells and ability 
to respond to differentiation signals.  Similar to cells of the early embryo, ES cells divide rapidly.  The cell cycle in 
ES cells is shortened in comparison to somatic cells, mainly due to abbreviated G1 phase and facilitated G1 to S 
transition (Becker et al., 2006).  Rapid progression through successive rounds of DNA replication and mitotic 
division may expose ES cells to increased risk of replication errors that may induce double strand breaks (DSB).  
The fact that ES cells can differentiate into numerous cell types emphasizes the importance of the safe-keeping of 
genomic integrity. 
In this study we investigated DNA damage responses in two types of pluripotent stem (PS) cells, namely 
embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells.  DNA damage response has been studied in 
great detail in somatic cells, and is comprised of coordinated cell cycle arrest, DNA repair, and apoptosis.  However, 
little is known about the events occurring following introduction of DNA damage into ES cells, and iPS cells are 
even less explored.  
Human ES and iPS cells are extremely sensitive to DNA damage and undergo cells death within hours of 
introduction of DNA lesions.  The hypersensitivity to DNA damaging agents has been reported in mouse and non-
human primate ES cells as well (Aladjem et al., 1998; Fluckiger et al., 2006; Hong and Stambrook, 2004), and 
appears to be a common characteristic of pluripotent stem cells representing one line of defense against genomic 
instability.  Both human ES and iPS cells activate checkpoint signaling cascade following γ-irradiation, leading to 
G2/M, but not G1/S arrest, similar to observations in mouse ES cells (Hong and Stambrook, 2004).  However, 
despite sharing similarities with mouse ES cells, human ES cell also show differences in DNA damage response, 
including robust phosphorylation and nuclear localization of CHEK2 and TP53 after irradiation.  It is interesting that 
even though checkpoint signaling is fully activated, ES cells do not arrest in G1/S phase.  G1 phase of the cell cycle 
has been argued to be a phase when ES cells are particularly sensitive to differentiation signals, which might explain 
the absence of G1/S arrest.  Indeed, direct reprogramming of somatic cells by transcription factors appears to 
eliminate G1/S arrest of the starting somatic cell population (iPS cells also show absence of G1/S arrest, and stop 
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their cycle in G2/M), suggesting it is a part of PS cell phenotype.  The fate of cells that are in G1 and early S phase at 
the time of irradiation is unknown, and would be interesting to investigate.  One speculation is that these cells would 
die before reaching G2 phase.  Taking into account the extent of cell death after irradiation this explanation is 
possible. However, even the cell death of the entire G1 population after irradiation does not explain the observed 
level of apoptosis. This further suggests that the cell cycle phase at the time of irradiation is not the only determinant 
affecting the life and death decision in PS cells.  Our results also demonstrate that cells that were in S phase of the 
cell cycle at the time of irradiation arrest at G2/M and continue cycling approximately 16 hours after irradiation.  We 
do not know, however, which percentage of initial population of cells in S phase survives and enters G1 phase after 
checkpoint recovery.  
Another curious observation is that within hours of UV irradiation or exposure to radiomimetic drugs, 
mouse ES cells decrease expression of pluripotency marker NANOG due to TP53-dependent repression (Lin et al., 
2005).  However, in this study we show that γ-irradiation results in a temporary reduction in NANOG gene 
expression, and that NANOG mRNA level returns to pre-irradiation level 24 hours later.  This suggests that perhaps 
in human ES cells NANOG down-regulation occurs concurrent with TP53 activation (six hours after irradiation), but 
when TP53 response fades, NANOG expression returns to steady state level.  It is possible that continuous exposure 
of ES cells to DNA damaging agents results in long-term TP53 activation and NANOG downregulation, which 
would lead to ES cell differentiation in the presence of persistent DNA damage.  However, acute DNA damage that 
leads to temporary activation of checkpoint signaling and cell cycle arrest may not necessarily induce differentiation 
of ES cells.  In agreement with this hypothesis, ES cells recover one week after irradiation and are able to produce 
teratomas in immunocompromised mice.  Even though iPS cells retain expression of pluripotency markers after 
irradiation, we have not tested their ability to form teratomas; it would be interesting to determine iPS cells’ 
differentiation potential after DNA damage and contrast it to findings in ES cells.  Together, these results suggest 
that at least some pluripotent stem cells survive irradiation, and raise interesting question of identity of cells that 
survive and those that undergo apoptosis. 
Following checkpoint recovery we observed higher incidence of aberrant mitotic figures, but the origin of 
these abnormal mitotic spindles in human ES cells remains unknown.  The observed defects in mitotic figures are 
classified to the following categories: misaligned chromosomes, multipolar spindles, lagging chromosomes, and 
anaphase bridges. Each of these defects may have distinct causes, and need to be further studied. For example, it has 
been demonstrated that irradiation induces supernumerary mitotic poles due to centrosomes amplification. Indeed, 
centrosome amplification occurs in numerous tumors and is a potential source of chromosome instability, 
chromosomal aberrations and aneuploidy.  It would be instrumental, then, to investigate the centrosomes cycle 
following irradiation and establish whether centrosomes undergo duplication in the absence of cellular division and 
when DNA cycle has been arrested.  In general, the issue of mitotic regulation is largely unexplored in ES cells.  
Mitotic spindles need to be formed in limited space due to tight packing of the cells in the colony, while still 
allowing accurate segregation of chromosomes between daughter cells.  Therefore, future studies need to address 
mitotic spindle formation and checkpoint function in ES cells. 
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While ATM function is clearly important for induction of G2/M cell cycle arrest, our results suggest there is 
an ATM independent pathway operating in irradiated human ES cells.  Following the inhibition of ATM with 
KU55933, a partial escape from cell cycle arrest can be observed two hours following irradiation of human ES cells, 
illustrating the role of ATM in cell cycle arrest.  However, the escape from G2/M is not complete, suggesting the 
existence of an additional cell cycle arrest mechanism.  A potential checkpoint target could be Polo-like kinase 1 
(PLK1).  This kinase is not only an important regulator of mitotic entry, but also necessary for the checkpoint 
recovery and entry of cells back into the cell cycle after the checkpoint response is completed (Macurek et al., 
2008).  Importantly, PLK1 was shown to play role in ATM-independent cell cycle arrest in somatic cells 
(Bassermann et al., 2008).  Its expression, localization, and function are unknown in human ES cells, and provide 
another interesting research topic. 
 The fact that ES and iPS cells restart the cell cycle by 24 hours post-irradiation implies that DNA damage 
has been repaired within this time period.  The timecourse immunocytochemistry of γ-H2AX demonstrated removal 
of most of the γ-H2AX foci by six hours after irradiation, which is in agreement with observed high capacity of 
human ES cells to repair multiple forms of DNA damage.  We hypothesized that in the population of self-renewing 
pluripotent stem cells error-free homologous recombination repair (HRR) would be the primary pathway for repair 
of double strand breaks (DSB). Both ES and iPS cells form RAD51 foci after irradiation suggesting HRR is taking 
place.  The gene and protein expression analysis revealed higher level of DNA repair transcripts and protein in ES 
and iPS cells relative to their undifferentiated counterparts.  Again, it appears that high capacity of DNA repair is a 
feature of pluripotent stem cells and participates in maintenance of genomic integrity in this cell type.  Interestingly, 
unlike in mouse ES cells (Banuelos et al., 2008; Tichy et al.), we observe high expression of genes and proteins 
involved in both HRR and error prone non-homologous end joining (NHEJ).  The role of NHEJ in human PS cells 
remains unknown and it would be beneficial to test the activity of this pathway in human ES cells by inhibiting or 
down-regulating key players in NHEJ in PS and determining its role in survival of ES cells after irradiation, as well 
as their ability to differentiate.   
 Taken together, we demonstrate several approaches to the maintenance of genomic stability in ES cells, 
including susceptibility to apoptosis in the presence of DNA damage, G2/M arrest that may favor error free 
homologous recombination repair of double strand breaks, and high level of expression of proteins involved in 
repair of multiple forms of DNA damage.  Finally, we report that reprogramming of somatic cells significantly alters 
DNA damage response, which becomes greatly similar to ES cells’ behavior after DNA damage, and represents 
characteristic of pluripotent state. 
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